Quinazoline derivatives.

MYPI1997000500A0Inactive Publication Date: 1997-08-14ASTRAZENECA UK LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1997000500
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
1996-02-14
Filing Date
1997-02-12
Publication Date
1997-08-14
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current anti-proliferative agents for cancer and psoriasis often inhibit DNA synthesis, leading to toxicity in both cancerous and normal cells, and there is a need for alternative approaches that can selectively target cancer cells by inhibiting receptor tyrosine kinases, which are frequently overexpressed in various human cancers.

Method used

Development of quinazoline derivatives with specific structural features that act as inhibitors of Class I receptor tyrosine kinases, such as EGF receptor tyrosine kinases, which are overexpressed in many human cancers and involved in cell proliferation disorders like psoriasis.

Benefits of technology

These quinazoline derivatives exhibit potent anti-proliferative effects by selectively inhibiting receptor tyrosine kinases, potentially offering a more targeted and less toxic treatment for various cancers and cell proliferation diseases by reducing tumor growth and inhibiting abnormal cell signaling.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

THE INVENTION CONCERNS QUINAZOLINE DERIVATIVES OF THE FORMULA I WHEREIN XL IS A DIRECT LINK OR A GROUP SUCH AS CO, C(R2)2 AND CH(OR2); WHEREIN Q1 IS PHENYL, NAPHTHYL OR A 5- OR 6-MEMBERED HETEROARYL MOIETY AND Q1 OPTIONALLY BEARS UP TO 3 SUBSTITUENTS; WHEREIN M IS 1 OR 2 AND EACH R1 MAY BE A GROUP SUCH AS HYDROGEN, HALOGENO AND TRIFLUOROMETHYL; AND WHEREIN Q2 MAY BE PHENYL OR A 9- OR 10-MEMBERED BICYCLIC HETEROCYCLIC MOIETY AND Q2 OPTIONALLY BEARS UP TO 3 SUBSTITUENTS; OR A PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF; PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THEIR RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER.
Need to check novelty before this filing date? Find Prior Art

Description

QUINAZOLINE DERIVATIVESThe invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said quinazoline derivatives, to pharmaceutical compositions containing them and to their use in tlie manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.Many of the current treatment regimes for cell proliferation diseases such as psoriasis and cancer utilise compounds which inhibit DNA synthesis. Such compounds are toxic to cells generally but their toxic effect on rapidly dividing cells such as tumour cells can be beneficial. Alternative approaches to anti-proli::erative agents which act by mechanisms other than the inhibition of DNA synthesis have the potential to display enhanced selectivity of action.In recent years it has been discovered that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene i.e. a gene which, on activation, leads to the formation of malignant tumour cells (Bradshaw, Mutagenesis. 1986,1, 91). Several such oncogenes give rise to the production of peptides which are receptors for growth factors. The growth factor receptor complex subsequently leads to an increase in cell proliferation. It is known, for example, that several oncogenes encode tyrosine kinase enzymes and that certain growth factor receptors are also tyrosine kinase enzymes (Yarden et al·, Ann. Rev, Biochem.. 1988, 57. 443; Larsen et al. Ann, Reports in Med, Chem. 1989,Chpt. 13).Receptor tyrosine kinases are important in the transmission of biochemical signals which initiate cell replication. They are large enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor (EGF) and an intracellular portion which functions as a kinase to phosphorylate tyrosine amino acids in proteins and hence to influence cell proliferation. Various classes of receptor tyrosine kinases are known (Wilks, Advances in Cancer Research. 1993, 60, 43-73) based on families of growth factors which bind to different receptor tyrosine kinases. The classification includes Class I receptor tyrosine kinases comprising the EGF family of receptor tyrosine kinases such as the EGF, transforming growth factor a (TGFa), NEU, erbB, Xmrk, DER and-2let23 receptors, Class II receptor tyrosine kinases c omprising the insulin family of receptor tyrosine kinases such as the insulin, IGFI and insulin-related receptor (IRR) receptors and Class III receptor tyrosine kinases comprising the platelet-derived growth factor (PDGF) family of receptor tyrosine kinases such as the PDGFa, PDGFp and colony-stimulating factor 1 (CSF1) receptors. It is known that Class I kinases such as the EGF family of receptor tyrosine kinases are frequently present in common human cancers such as breast cancer (Sainsbury et al., Brit. J. Cancer. 1988, 58.458; Guerin et aL, Oncogene Res., 1988,1, 21 and Klijn et al., Breast Cancer Res. Treat.. 1994, 29. 73), non-small cell lung cancers (NSCLCs) including adenocarcinomas (Cemy et al., Brit. J, Cancer. 1986, 54, 265; Reubi St al., Int, J, Cancer. 1990, 45. 269 and Rusch et al., Cancer Research. 1993, 53, 2379) and squamous cell cancer of the lung (Hendler et al., Cancer Cells, 1989, 7, 347), bladder cancer (Neal et al., Lancet. 1985, 366), oesophageal cancer (Mukaida et al., Cancer. 1991, 68, 142), gastrointestinal cancer such as colon, rectal or stomach cancer (Bolen et al.. Oncogene Res., 1987,1, 149), cancer of the prostate (Visakorpi et ,=tl-, Histochem. J„ 1992, 24, 481), leukaemia (Konaka et al., Cell. 1984, 37. 1035) and ovarian, bronchial or pancreatic cancer (European Patent Specification No. 0400586). As further human tumour tissues are tested for the EGF family of receptor tyrosine kinases it is expected that its widespread prevalance will be established in further cancers such as thyroid and uterine cancer. It is also known that EGF type tyrosine kinase activity is rarely detected in normal cells whereas it is more frequently detectable in malignant cells (Hunter, Cell. 1987, 50, 823). It has been shown more recently (W J Gullick, Brit. Med, Bull.. 1991, 47. 87) that EGF receptors which possesses tyrosine kinase activity are overexpressed in many human cancers such as brain, lung squamous cell, bladder, gastric, colorectal, breast, head and neck, oesophageal, gynaecological and thyroid tumours.Accordingly it has been recognised that tin inhibitor of receptor tyrosine kinases should be of value as a selective inhibitor of the growth of mammalian cancer cells (Yaish et al. Science, 1988, 242, 933). Support for this view is provided by the demonstration that erbstatin, an EGF receptor tyrosine kinase inhibitor, specifically attenuates the growth in athymic nude mice of a transplanted human mamn jary carcinoma which expresses EGF receptor tyrosine kinase but is without effect on the growth of another carcinoma which does not express EGF receptor tyrosine kinase (Toi et al., Eur, J, Cancer Clin, Oncol.. 1990, 26. 722). Various derivatives of styrene are also stated to possess tyrosine kinase inhibitory-3properties (European Patent Application Nos. 0211.363, 0304493 and 0322738) and to be of use as anti-tumour agents. The in vivo inhibitory effect of two such styrene derivatives which are EGF receptor tyrosine kinase inhibitors has been demonstrated against the growth of human squamous cell carcinoma inoculated into nude mice (Yoneda et ah, Cancer Research. 1991, 51, 4430). Accordingly it has been indicated that Class I receptor tyrosine kinase inhibitors will prove to be useful in the treatment of a variety of human cancers. Various known tyrosine kinase inhibitors are disclosed in a more recent review by T R Burke Jr.(Drugs of the Future, 1992, 17. 119).EGF type receptor tyrosine kinases have also been implicated in non-malignant proliferative disorders such as psoriasis (Elder et al., Science. 1989, 243. 811). It is therefore expected that inhibitors of EGF type receptor tyrosine kinases will be useful in the treatment of non-malignant diseases of excessive cellular proliferation such as psoriasis (where TGFa is believed to be the most important growth factor) and benign prostatic hypertrophy (BPH), atherosclerosis and restenosis.It is known from European Patent Applications Nos. 0520722 and 0566226 and from International Patent Applications WO 95 / 15758, WO 95 / 19169, WO 96 / 09294,WO 96 / 15118, WO 96 / 16960 and WO 96 / 30347 tliat certain quinazoline derivatives which bear an anilino substituent at the 4-position possess receptor tyrosine kinase inhibitory activity. It is further known from European Patent Application No. 0602851 and from International Patent Application WO 95 / 23141 that certain quinazoline derivatives which bear a heteroarylamino substituent at the 4-position also possess receptor tyrosine kinase inhibitory activity.It is further known from International Parent Application WO 92 / 20642 that certain aryl and heteroaryl compounds inhibit EGF and / or PDGF receptor tyrosine kinase. There is the disclosure of certain quinazoline derivatives therein but no mention is made of4-anilinoquinazoline derivatives.It is further known from European Patent Application No. 0635507 and from International Patent Applications WO 95 / 06648, WO 95 / 19970 and WO 96 / 29331 that certain tricyclic compounds which comprise a 5- or 6-membered ring fused to the benzo-ring of a quinazoline possess receptor tyrosine kinase inhibtory activity or phosphodiesterase inhibitory activity. It is also known from European Patent Application No. 0635498 that-4certain quinazoline derivatives which carry an amino group at the 6-position and a halogeno group at the 7-position possess receptor tyrosine kinase inhibitory activity.The in vitro anti-proliferative effect of a 4-anilinoquinazoline derivative has been disclosed by Fry et al., Science, 1994, 265, 1093. It was stated that the compound4-(3-bromoanilino)-6,7-dimethoxyquinazoline was a highly potent inhibitor of EGF receptor tyrosine kinase.The in vivo inhibitory effect of a 4,5-dianilinophthalimide derivative which is an inhibitor of the EGF family of receptor tyrosine ki nases has been demonstrated against the growth in BALB / c nude mice of a human epidermoid carcinoma A-431 or of a human ovarian carcinoma SKOV-3 (Buchdunger et al., Proc. Nat, Acad. Sci.. 1994, 21, 2334).It is further disclosed in International Patent Applications WO 96 / 33977,WO 96 / 33978, WO 96 / 33979, WO 96 / 33980 and WO 96 / 33981 that certain further quinazoline derivatives which bear an anilino substituent at the 4-position possess receptor tyrosine kinase inhibitory activity.There is no disclosure in these documents of quinazoline derivatives which bear a heteroaryl moiety attached directly to the 6-positicn (other than the disclosure in International Patent Application WO 96 / 16960 of certain 4-anilinoquinazolines which bear a 5- or 9-membered nitrogen-linked heteroaryl moiety at the 6-position) or attached to the 6-position by way of a 1- or 2-atom chain, or of an aryl moiety attached directly to the 6-position or attached to the 6-position by way of a 1- or 2-atom chain [other than the disclosure inEuropean Patent Application No. 0566226 of certain 4-anilinoquinazolines which bear an aryl moiety attached to the 6-position by way of a CONH, NHCH2, CH2NH or SCH2linking chain (with the aryl moiety attached to the first atom of these 2 atom linking groups, for example the carbon atom within the CONH group)].We have now found that such compounds possess anti-proliferative properties which are believed to arise from their Class I (EGF type) receptor tyrosine kinase inhibitory activity.According to the invention there is provided a quinazoline derivative of the formula I-5Q2Xwherein X1is a direct link or a group of the formula CO, C(R2)2, CH(OR2), C(R2)2-C(R2)2, C(R2)=C(R2), C=C, CH(CN), O, S, SO, SO2, N(R2j, CON(R2), SO2N(R2), N(R2)CO, N(R2)SO2, OC(R2), SC(R2)2, N(R2)C(R2)2, C(R2)2O, C(R2)2S or C(R2)2N(R2), and each R2is independently hydrogen or (l-4C)alkyl;wherein Q1is phenyl, naphthyl or a 5- or 6-membe::ed heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur, which heterocyclic moiety is a single ring or is fused to a benzo ring, and Q1optionally bears up to 3 substituents selected from halogeno, hydroxy, amino, trifluoromethoxy, trifluoromethyl, cyano, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkynyloxy, (l-3C)alkylenedioxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, pyrrolidin-l-yl, piperidino, morpholino, piperazin-l-yl, 4-(l-4C)alkylpiperazin-l-yl, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl, N,N-di-[(l-4C)alkyl]carbamoyl, amino-(l-4C)alkyl, (l-4C)alkylamino-(l-4C)alkyl, di-[(l-4C)alkyl]amino-(l-4C)alkyl, pyrrolidin-1 -y 1-( 1 -4C)alkyl, piperidino-( 1 -4C)alkyl, morpholino-( 1 -4C)alkyl, piperazin-1 -y 1-( 1 -4C)alkyl, 4-(1 -4C)alkylpiperazinl -y 1-( 1 -4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (1 -4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (l-4C)alkylamino-(2-4C)alkoxy, di-[(l-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-l-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy, 4-(l-4C)alkylpiperazin-l-yl-(2-4C)alkoxy, (l-4C)alkylthio-(2-4C)alkoxy, (l-4C)alkylsulphinyl-(2-4C)alkoxy, (1 -4C)alkylsulphonyl-(2-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (1 -4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (l-4C)alkylamino-(2-4C)alkylamino, di-[(l-4C)alkvl]amino-(2-4C)alkylamino, pyrrolidin-1 -yl-(2-4C)alkylamino, piperidino-(2-4C')alkylamino,-6morpholino-(2-4C)alkylamino, piperazin-1 -y 1-(2-4 Qalkylamino,4-(1 -4C)alkylpiperazin-1 -yl-(2-4C)alkylamino, N- (1 -4C)alkyl-halogeno-(2-4C)alkylamino, N-(l-4C)alkyl-hydroxy-(2-4C)alkylamino, N-(l-4C)alkyl-(l-4C)alkoxy-(2-4C)alkylamino, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino, (l-4C)alkoxy-(2-4C)alkanoylamino, (3-4C)alkenoylamino, (3-4C)alkynoylamino, amino-(2-4C)alkanoylamino, (1 -4C)alkylamino-(2-4C)alkanoylamino, di-[(l-4C)alkyl]amino-(2-4C)alkanoylamino, pyrrolidin-l-yl-(2-4C)alkanoylamino, piperidino-(2-4C)alkanoylamino, morpholino-(2-4C)alkanoylamino, piperazin-1 -yl-(2-4C)alkanoylamino and 4-( 1 -4C)alkylpiperazin-1 -yl-(2-4C)alkanoylamino, and wherein any of the above-mentioned substitue nts comprising a CH2(methylene) group which is not attached to a halogeno, SO or SO2group or to a Ν, O or S atom optionally bears on said CH2group a substituent selected from hyd 'oxy, amino, (l-4C)alkoxy, (l-4C)alkylamino and di-[(l-4C)alkyl]amino;wherein m is 1 or 2 and each R1is independently hydrogen, halogeno, trifluoromethyl, hydroxy, amino, nitro, cyano, carboxy, carbamoyl. (l-4C)alkoxycarbamoyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl or N,N-di-[(l-4C)alkyl]carbamoyl;and wherein Q is phenyl or a 9- or 10-membered bicyclic heterocyclic moiety containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from oxygen, nitrogen and sulphur, and Q optionally bears up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-(l-4C)alkylcarbamoyl, or Q is a group of the formula IIwherein X2is a group ofthe formula CO, C(R3)2, CH(OR3), C(R3)2-C(R3)2, C(R3)=C(R3), C^C, CH(CN), O, S, SO, SO2, N(R3), CON(R3), SO2N(R3), N(R3)CO, N(R3)SO2, OC(R3)2, SC(R3)2, C(R3)2O or C(R3)2S wherein each R3is independently hydrogen or (l-4C)alkyl,-ΊQ is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur, which heteroaryl moiety is a single ring or is fused to a benzo ring, and wherein said phenyl or naphthyl group or heteroaryl moiety optionally bears up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-[(l-4C)alkyl]carbamoyl, n is 1, 2 or 3 and each R4is independently hydrogen, halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino or (2-4C)alkanoylamino;or a pharmaceutically-acceptable salt thereof;provided that, when Q1is optionally-substituted phenyl, X1is not N(R2)CO, N(R2)SO2, OC(R2)2, N(R2)C(R2)2, C(R2)2S or C(R2)2N(R2); and when X1is a direct link, Q1is not a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to 3 nitrogen heteroatoms.According to a further aspect of the invention there is provided a quinazoline derivative of the formula I wherein X1is a direct link or a group of the formula CO, C(R2)2, CH(OR2), C(R2)2-C(R2)2, C(R2)=C(R2), C=C, CH(CN), O, S, SO, SO2, N(R2), CON(R2), SO2N(R2), N(R2)CO, N(R2)SO2, OC(R2)2, SC(R2)2, N(R2)C(R2)2, C(R2)-O, C(R2)2S or C(R2)2N(R2), and each R2is independently hydrogen or (l-4C)alkyl;wherein Q1is a 5- or 6-membered heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur, which heterocyclic moiety is a single ring or is fused to a benzo ring, and Q1optionally bears up to 3 substituents selected from halogeno, hydroxy, amino, trifluoromethoxy, trifluoromethyl, cyano, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (2-4C)alkenyloxy, (2-4C)alkynyloxy, (l-3C)alkylenedioxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, pyrrolidin-l-yl, piperidino, morpholino, piperazin-l-yl, 4-(l-4C)alkylpiperazin-l-yl, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl, N,N-di-[(l-4C)alkyl]carbamoyl, amino-( 1 -4C)alkyl, (1 -4C)alkylamino-( 1 -4C)alkyl, di-[( 1 -4C)alkyl]amino-( 1 -4C)alkyl, pyrrolidin-1 -yl-( 1 -4C)alkyl, piperidino-( 1 -4C)alkyl, morpholino-( 1 -4C)alkyl,-8piperazin-1 -yl-( 1 -4C)alkyl, 4-( 1 -4C)alkylpiperaziri-1 -yl-( 1 -4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (1 -4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (l-4C)alkylamino-(2-4C)alkoxy, di-[(l-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1 -yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1 -yl-(2-4C)alkoxy, 4-( 1 -4C)alkylpipera2;:in-1 -yl-(2-4C)alkoxy, (l-4C)alkylthio-(2-4C)alkoxy, (l-4C)alkylsulphinyl-(2-4C)alkoxy, (1 -4C)alkylsulphonyl-(2-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (1 -4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (1 -4C)alkylamino-(2-4C)alkylamino, di-[( 1 -4C)alkyl]amino-(2-4C)alkylamino, pyrrolidin-1 -yl-(2-4C)alkylamino, piperidino-(2-4C)alkylamino, morpholino-(2-4C)alky lamino, piperazin-1 -y 1-(2-4 Qalkylamino,4-( 1 -4C)alkylpiperazin-1 -yl-(2-4C)alkylamino, N-( 1 -4C)alkyl-halogeno(2-4C)alkylamino, N-(l -4C)alkyl-hydroxy-(2-4C)alkylamino, N-(l-4C)alkyl-(l-4C)alkoxy-(2-4C)alkylamino, hiilogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino, (1 -4C)alkoxy-(2-4 C)alkanoylamino, (3 -4C)alkenoylamino, (3-4C)alkynoylamino, amino-(2-4C)alkanoylamirLO, (1 -4C)alkylamino-(2-4C)alkanoy lamino, di-[(1 -4C)alkyl]amino-(2-4C)alkanoylamino, pyrrolidin-1 -yl-(2-4C)alkanoylamino, piperidino-(2-4C)alkanoylamino, morpholino-(2-4C)alkanoylamino, piperazin-1 -yl-(2-4C)alkanoylamino and 4-( 1 -4C)alkylpiperazin-1 -yl-(2-4C)alkanoylamino, and wherein any of the above-mentioned substitue nts comprising a CH2(methylene) group which is not attached to a halogeno, SO or SO2group or to a N, O or S atom optionally bears on said CH2group a substituent selected from hydroxy, amino, (l-4C)alkoxy, (l-4C)alkylamino and di-[(l-4C)alkyl]amino;wherein m is 1 or 2 and each R1is independently hydrogen, halogeno, trifluoromethyl, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (l-4C)alkoxycarbamoyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl or N,N-di-[(l-4C)alkyl]carbamoyl;and wherein Q is phenyl which optionally bears up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-(l-4C)alkylcarbamoyl;or a pharmaceutically-acceptable salt thereof;-9provided that, when X1is a direct link, Q1is not a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to 3 nitrogen heteroatoms.In this specification the term alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as propyl are specific for the straight chain version only. For example when R1is a hydjroxy-(2-4C)alkoxy group, suitable values for this generic radical include 2-hydroxyethoxy, 2-hydroxypropoxy, 1 -hydroxyprop-2-yloxy and 3-hydroxypropoxy. An analogous convention applies to other generic terms.Within the present invention it is to be understood that a quinazoline derivative of the formula I may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which possesses anti-proliferative activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.The quinazolines of the formula I are unsubstituted at the 2-position thus it is to be understood that the R1groups are located only on the benzo portion of the quinazoline ring.It is also to be understood that certain quinazoline derivatives of the formula I can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess anti-proliferative activity.Suitable values for the generic radicals referred to above include those set out below.A suitable value for a substituent on Q , Q or Q , for a substituent on a CH2group within a substituent on Q1, or for R1, R2, R3or R4when it is halogeno is, for example, fluoro, chloro, bromo or iodo;when it is (l-4C)alkyl is, for example, methyl, ethyl, propyl, isopropyl or butyl;when it is (l-4C)alkoxy is, for example, methoxy, ethoxy, propoxy, isopropoxy or butoxy; when it is (l-4C)alkylamino is, for example, methylamino, ethylamino or propylamino; when it is di-[(l-4C)alkyl]amino is, for example, dimethylamino, diethylamino, N-ethyl-H-methylamino or dipropylamino;when it is (2-4C)alkanoylamino is, for example, acetamido, propionamido or butyramido;when it is (l-4C)alkoxy carbonyl is, for example, methoxy carbonyl, ethoxycarbonyl, propoxycarbonyl, butoxcarbonyl or tert-butoxycarbonyl;when it is N-(l-4C)alkylcarbamoyl is, for example;, N-methylcarbamoyl or N-ethylcarbamoyl;- 10and when it is N,N-di-[(l-4C)alkyl]carbamoyl is, for example, N,N-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl and N,N-diethylcarbamoyl.Suitable values for each substituent which may be present on Q1include, for example :for (2-4C)alkenyloxy:for (2-4C)alkynyloxy:for (l-3C)alkylenedioxy:for 4-(l-4C)alkylpiperazin-l-yl:for amino-(l-4C)alkyl:for (1 -4C)alkylamino-( 1 -4C)alkyl:for di-[(1 -4C)alkyl]amino-(l -4C)alkyl:for pyrrolidin-l-yl-(l-4C)alkyl:for piperidino-(l-4C)alkyl:for morpholino-(l-4C)alkyl:for piperazin-l-yl-(l-4C)alkyl:for 4-( l-4C)alky lpiperazin-1-yl(l-4C)alkyl:for halogeno-(2-4C)alkoxy:vinyloxy and allyloxy;2-propynyloxy;methylenedioxy, ethylenedioxy and propylemedioxy;4-methylpiperazin-l-yl and4-ethylpiperazin-1 -yl;aminomethyl, 2-aminoethyl and 3-aminopropyl; methylaminomethyl, 2-methylaminoethyl and 3 -methy laminopropy 1;dimethylaminomethyl, diethylaminomethyl,2- dimelhylaminoethyl, 2-diethylaminoethyl and3- dimelhylaminopropyl;pyrrolidin-l-ylmethyl, 2-pyrrolidin-l-ylethyl and 3 -pyrro lidin-1 -ylpropyl; piperidinomethyl, 2-piperidinoethyl and 3 -piper dinopr opy 1;morphclinomethyl, 2-morpholinoethyl and 3 -morp holinopr opy 1;piperazin-l-ylmethyl, 2-piperazin-l-ylethyl and 3 -piperazin-1 -ylpropyl;4- methy lpiperazin-1 -ylmethyl,2- (4-methylpiperazin-1 -yl)ethyl and3- (4-methy lpiperazin-1 -yl)propyl;2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy,-fluoropropoxy, 3 -chloropropoxy,2,2,2-tr ifluoroethoxy, 1,1,2,2,2-pentafluoroethoxy,2.2.3.3- tetrafluoropropoxy, 2.2.3.3.3- pentafluoropropoxy and 1.1.2.2.3.3.3- heptafluoropropoxy; for hydroxy-(2-4C)alkoxy: 2-hydroxy ethoxy, 3-hydroxypropoxy and 4-hydro xy butoxy; for (l-4C)alkoxy-(2-4C)alkoxy: 2- methcxyethoxy, 2-ethoxyethoxy, 3- methcxypropoxy and 3-ethoxypropoxy; for amino-(2-4C)alkoxy: 2-amincethoxy and 3-aminopropoxy; for (l-4C)alkylamino-(2-4C)- alkoxy: 2-methylaminoethoxy, 2-ethylaminoethoxy, 2-propylaminoethoxy, 3-methylaminopropoxy and 3 -ethylaminopropoxy; for di-[(l-4C)alkyl]amino- (2-4C)alkoxy: 2-dimethylaminoethoxy, 2-(N-ethyl-N-methylamino)ethoxy, 2- diethylaminoethoxy, 2-dipropylaminoethoxy, 3- dimethylaminopropoxy and 3 -diethy laminopropoxy; for pyrrolidin-l-yl-(2-4C)- alkoxy: 2- (pyrrolidin-l-yl)ethoxy and 3- (pyrrolidin-l -yl)propoxy; for piperidino-(2-4C)alkoxy: 2-piperidinoethoxy and 3-piperidinopropoxy; for morpholino-(2-4C)alkoxy: for piperazin-l-yl-(2-4C)alkoxy: 2-morpholinoethoxy and 3-morpholinopropoxy; 2- (piperazin-l-yl)ethoxy and 3- (piperazin-1 -yl)propoxy; for 4-( 1 -4C)alkylpiperazin-1 -yl- (2-4C)alkoxy: 2- (4-meithylpiperazin-l -yl)ethoxy and 3- (4-meithylpiperazin-1 -yl)propoxy; for (l-4C)alkylthio-(2-4C)alkoxy: 2-methylthioethoxy and 3-methylthiopropoxy; for (l-4C)alkylsulphinyl-(2-4C)- alkoxy: 2- methylsulphinylethoxy and 3- methylsulphinylpropoxy;- 12for (l-4C)alkylsulphonyl-(2-4C)alkoxy:for halogeno-(2-4C)alkylamino:for hydroxy-(2-4C)alkylamino:for (l-4C)alkoxy-(2-4C)alkyl10 amino:for amino-(2-4C)alkylamino:for (l-4C)alkylamino15 (2-4C)alkylamino:for di-[(l-4C)alkyl]amino(2-4C)alkylamino:for pyrrolidin-l-yl-(2-4C)alkylamino:for piperidino-(2-4C)alkylamino:2-methyllsulphonylethoxy and-methy llsulphony lpropoxy;2-fluoroethylamino, 2-chloroethylamino,2-bromoethylamino, 3-fluoropropylamino and 3 -chloropropy lamino;2-hydroxy ethylamino, 3-hydroxypropylamino and4-hydro xybutylamino;2- methoxyethylamino, 2-ethoxyethylamino,3- methcxypropylamino and 3-ethoxypropylamino; 2-aminc ethylamino, 3-aminopropylamino and4- amincbutylamino;2- methylaminoethylamino, 2-ethylaminoethylamino, 2-propylaminoethylamino,-methy laminopropylamino,3- ethylaminopropylamino and4- methy laminobuty lamino;2-dimetbylaminoethylamino,2-(N-ethyl-N-methylamino)ethylamino,2-diethy laminoethylamino,2- dipropylaminoethylamino,-dimetby laminopropylamino,3- diethy laminopropylamino and4- dimethylaminobutylamino;2-(pyrrelidin-1 -yl)ethylamino and 3 -(pyrro Lidin-1 -yl)propy lamino; 2-piperidinoethylamino and 3 -piperidinopropy lamino;- 13 for morpholino-(2-4C)alkylamino:for piperazin-1-yl-(2-4C)alkylamino:for 4-(l-4C)alkylpiperazin-l-yl(2-4C)alky lamino:for N-(l -4C)alkyl-halogeno10 (2-4C)alkylamino:for N-( 1 -4C)alkyl-hydroxy-(2-4C)alkylamino:for N-( 1 -4C)alky 1-( 1 -4C)alkoxy(2-4C)alkylamino:for halogeno-(2-4C)alkanoylamino:for hydroxy-(2-4C)alkanoylamino:for (l-4C)alkoxy-(2-4C)alkanoy lamino:for (3-4C)alkenoylamino:2-morpholinoethylamino and 3 -morpholinopropylamino;2- (piperazin-l-yl)ethylamino and3- (piperazin-1 -yl)propylamino;2-(4-methylpiperazin-1 -yl)ethylamino and 3 -(4-methylpiperazin-1 -yl)propylamino;N-(2-chloroethyl)-N-methylamino,N-(2-bromoethyl)-N-methylamino and N-(2-bromoethyl)-N-ethylamino;N-(2-hydroxyethyl)-N-methylamino,N-(3 -hydroxypropyl)-N-methylamino and N-ethyl-N-(2-hydroxyethyl)amino;N-methyl-N-(2-methoxyethyl)amino,N-methyl-N-(3 -methoxypropyl)amino and N-ethyl-N-(2-methoxyethyl)amino;2- chloroacetamido, 2-bromoacetamido,3- chloropropionamido and 3-bromopropionamido; 2-hydroxyacetamido, 3-hydroxypropionamido and4- hy dro xy buty ramido;2-methoxyacetamido, 2-ethoxyacetamido,2- propoxyacetamido, 3-methoxypropionamido,3- ethoxypropionamido and 4-methoxybutyramido; acrylamido, methacrylamido, crotonamido and isocrotonamido;for (3-4C)alkynoylamino: for amino-(2-4C)alkanoylamino: propiolamido; 2-aminoacetamido, 2-aminopropionamido and 3 -aminopropionamido; for (l-4C)alkylamino-(2-4C)- alkanoylamino: 2-methylaminoacetamido, 2-ethylaminoacetamido, 2-methylaminopropionamido and 3 -methy llaminopropionamido; for di-[(l-4C)alkyl]amino-(2-4C)- alkanoylamino: 2-dimethylaminoacetamido, 2-diethy laminoacetamido, 2-dimefaylaminopropionamido and 3 -dimet ay laminopropionamido; for pyrrolidin-l-yl-(2-4C)- alkanoylamino: 2-pyrrol iidin-1 -ylacetamido, 2-pyrrol iidin-1 -ylpropionamido and 3 -pyrrol iidin-1 -ylpropionamido;for piperidino-(2-4C)- alkanoylamino: 2-piperidinoacetamido, 2-piperidinopropionamido and 3-p:.peridinopropionamido; for morpholino-(2-4C)- alkanoylamino: 2-morpholinoacetamido, 2-morpholinopropionamido and 3 -morpholinopropionamido; for piperazin-l-yl-(2-4C)- alkanoylamino: 2-piperazin-1 -ylacetamido, 2- piperazin-l -ylpropionamido and 3- piperazin-1 -ylpropionamido; for 4-(l-4C)alkylpiperazin-l-yl- (2-4C)alkanoylamino: 2-(4-methylpiperazin-1 -yl)acetamido, 2- (4-methylpiperazin-1 -yl)propionamido and 3- (4-methylpiperazin-1 -yl)propionamido.- 15 When there is a (l-3C)alkylenedioxy substituted on Q1, the oxygen atoms thereof occupy adjacent positions on the Q1ring.When m is 1 the R1substituent is preferably located at the 7-position of the quinazoline ring.Suitable substituents formed when any of the substituents on Q1comprising a CH2group which is not attached to a halogeno, SO or SO2group or to a Ν, O or S atom bears on said CH2group a substituent selected from hydroxy, amino, (l-4C)alkoxy, (l-4C)alkylamino and di-[(l-4C)alkyl]amino include, for example, substituted (l-4C)alkylamino-(2-4C)alkoxy or di-[(l-4C)alkyl]amino-(2-4C)alkoxy groups, for example hydroxy-(l-4C)alkylamino-(2-4C)alkoxy or hydroxy-di-[(l-4C)alkyl]amino-(2-4C)alkoxy groups such as 3-methylamino-2-hydroxypropoxy and 3-dimethylamino-2-hydroxypropoxy.3A suitable value for Q and Q when it is a naphthyl group is, for example,1-naphthyl or 2-naphthyl.3A suitable value for Q or Q when it is a 5- or 6-membered heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur, which is a single ring is, for example, furyl, pyrrolyl, thienyl, pyridyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,3-triazolyl,1,2,4-triazolyl, oxadiazolyl, furazanyl or thiadiazoylyl, or which is fused to a benzo ring is, for example, benzofuryl, indolyl, benzothienyl, quinolyl, isoquinolyl, benzoxazolyl, indazolyl, benzimidazolyl, benzothiazolyl, cinnolinyl, quina2;olinyl, quinoxalinyl or benzotriazolyl. Said heteroaryl moiety may be attached to X and X through any available position. The optional substituents on Q1or Q3may be located at any ava ilable position including on any available nitrogen heteroatom.A suitable value for Q when it is 9- or 1'3-membered bicyclic heterocyclic moiety containing 1 or 2 nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur is, for example, a benzo-fused heterocyclic moiety such as indolyl, isoindolyl, indolizinyl, lH-benzimidazolyl, ΙΗ-indazolyl, benzoxazolyl, benzo[c]isoxazolyl, benzo[djisoxazolyl, benzothiazolyl, benzo[c]isothiazolyl, benzo[djisothiazolyl, lH-benzotriazolyl, benzo[c]furazanyl, benzo[c][2,l,3]thiadiazolyl, benzo[d][l,2,3]oxadiazolyl, benzo[d][l,2,3]thiadiazolyl, quinolyl, 1,2-dihydroquinolinyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 4H-l,4-benzoxazinyl or 4H-1,4-benzothiazinyl.- 16The heterocyclic moiety may be attached through any available position including from either of the two rings of the bicyclic heterocyclic moiety. The heterocyclic moiety may bear a suitable substituent such as a (l-4C)alkyl substituent on an available nitrogen atom.It is also to be understood that, within the structure of formula I, when X1is, for 5 example, a group of the formula C(R )2O, it is the C atom which is attached to the quinazoline ring and the O atom which is attached to Q . Like wise, when X is, for example, a group of οthe formula N(R )SO2, it is the N atom which is attached to the phenylene ring and the SO23 1 group which is attached to Q . Likewise, when X is, for example, a group of the formula CON(R ), it is the CO group which is attached to the quinazoline ring and the N atom which is attached to Q1.A suitable pharmaceutically-acceptable salt of a quinazoline derivative of the invention is, for example, an acid-addition salt of a quinazoline derivative of the invention which is sufficiently basic, for example, a mono- or di-acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a quinazoline derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.Particular novel compounds of the inven tion include, for example, quinazoline derivatives of the formula I, or pharmaceutically-a cceptable salts thereof, wherein, unless otherwise stated, each of Q , X , m, R and Q has any of the meanings defined hereinbefore or in this section concerning particular compounds of the invention:25 (a) X1is a direct link;(b) X1is a group of the formula CO, CH2, CH(OH), CH2CH2, CH=CH, C=C, O, S, SO, SO2, NH, CONH, SO2NH, NHCO, NHSO2, OCH2, SCH2, NHCH2, CH2O, CH2S or CH2NH;(c) X* is a group ofthe formula CH2, CH2CH2, O, S, SO, SO2, NH, NHCO, NHSO2, OCH2or NHCH2;(d) Q1is phenyl optionally substituted as defined hereinbefore;- 17(e) Q1is a 5- or 6-membered monocyclic heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur which is optionally substituted as defined hereinbefore;(f) Q1is furyl, pyrrolyl, thienyl, pyridyl, oxizolyl, isoxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,3-triazolyl or 1,2,4-triazolyl which is attached from any available position including from a nitrogen atom and which is optionally substituted as defined hereinbefore;(g) Q1bears no optional substituents;(h) Q1bears 1 or 2 substituents selected from halogeno, hydroxy, amino, trifluoromethoxy, trifluoromethyl, cyano, nitro, (1 -4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino and (2-4C)alkanoylamino;(i) Q1bears a substituent selected from amino-(l-4C)alkyl, (l-4C)alkylamino(1 -4C)alky 1, di- [(1 -4C)alkyl] amino-( 1 -4C)alky 1, pyrrolidin-1 -yl-( 1 -4C)alky 1, piperidino-(l-4C)alkyl, morpholino-(l-4C)alkyl, piperazin-l-yl-(l-4C)alkyl and4-( 1 -4C)alky lpiperazin-1 -yl-( 1 -4C)alkyl;(j) m is 1 and R1is hydrogen;(k) m is 1 and R1is (l-4C)alkoxy;(l) Q is phenyl which is optionally substituted as defined hereinbefore;(m) Q is a group of the formula IIII wherein X2is a group of the formula CO, CH2, CH(OH),“S, SO2NH or OCH2, Q3is phenyl or pyridyl which optionally bears 1 or 2 substituents selected from halogeno, (l-4C)alkyl and (l-4C)alkoxy, n is 1 and R4is hydrogen, halogeno, (l-4C)alkyl or (l-4C)alkoxy;(n) Q is a group of the formula II wherein X is a group of the formula CO, Q is phenyl which optionally bears 1 or 2 substituents selected from halogeno, (l-4C)alkyl and (l-4C)alkoxy, n is 1 and R4is hydrogen, halogeno or (l-4C)alkyl; and-182 2 3 (o) Q is a group of the formula II wherein X is a group of the formula OCH2, Q is pyridyl, n is 1 and R4is hydrogen, halogeno or (l-4C)alkyl;provided that when Q1is optionally-substituted phenyl, X1is not N(R2)CO, N(R2)SO2, OC(R2)2, N(R2)C(R2)2, C(R2)2S or C(R2)2N(R2); and when X1is a direct link, Q1is not a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to 3 nitrogen heteroatoms.A preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link or a group of the formula CH2, CH2CH2, NH, NHCO, NHSO2, OCH2, SCH2, NHCH2, CH2O or CH2S;Q’is 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-oxazolyl,4- oxazolyl, 5-isoxazolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, 2-thiazolyl, 4-thiazolyl,5- isothiazolyl or l,2,3-triazol-4-yl which optionally bears a substituent selected from methyl, aminomethyl, 2-aminoethyl, methylaminomethyl, 2-methylaminoethyl, dimethylaminomethyl, 2-dimethylaminoethyl, pyrrolidin-1-ylmethyl, 2-pyrrolidin-l-ylethyl, piperidinomethyl, 2-piperidinoethyl, morpholinomethyl, 2-morpholinoethyl, piperazin- 1-ylmethyl, 2-piperazin-l-ylethyl, 4-me1:hylpiperazin-1-ylmethyl and2-(4-methylpiperazin-1 -y l)ethyl;m is 1 and R1is hydrogen or methoxy;and Q is phenyl which optionally bears 1, 2 or 3 substituents selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl and methoxy, or Q is a group of the formula II3 .wherein X is a group of the formula CO or OCH2, Q is phenyl or 2-pyridyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo, methyl and methoxy, n is 1 and R4is hydrogen, fluoro, chloro, bromo or methyl;or a pharmaceutically-acceptable acid-addition salt thereof.A further preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link or a group of the formula NHCO, OCH2or NHCH2;- 19Q1is 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-oxazolyl, 5-isoxazolyl or 4-imidazolyl which optionally bears a substituent selected from aminomethyl, morpholinomethyl and 2-morpholinoethyl;m is 1 and R1is hydrogen or methoxy;and Q is phenyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo and methyl;or a pharmaceutically-acceptable acid-addition salt thereof.A specific especially preferred compound of the invention is the quinazoline derivative ofthe formula I:4-(3-chloro-4-fluoroanilino)-6-(3-furyl)quinazoline,4-(3-chloro-4-fluoroanilino)-6-(2-thienyl)quinazoline,4-(3-chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline,4-(3-chloro-4-fluoroanilino)-6-(5-morpholinomethylthien-3-yl)quinazoline or4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-pyridylmethoxy)quinazoline;or a pharmaceutically-acceptable acid-addition salt thereof.A further preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link;Q1is thienyl which bears a substituent selected from amino-(l-4C)alkyl, (l-4C)alkylamino(1 -4C)alkyl, di-[( 1 -4C)alkyl]amino-( 1 -4C)alkyl, py rrolidin-1 -yl-( 1 -4C)alkyl, piperidino-(l-4C)alkyl, morpholino-(l-4C)alkyl, piperazin-l-yl-(l-4C)alkyl and 4-(1 -4C)alky lpiperazin-1 -y 1-( 1 -4C)alkyl;m is 1 and R1is hydrogen;and Q is phenyl which optionally bears up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-(l-4C)alkylcairbamoyl;or a pharmaceutically-acceptable salt thereof.A further preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link;Q1is 2-thienyl which optionally bears a substituent selected from methyl, aminomethyl,-202-aminoethyl, methylaminomethyl, 2-methylamineethyl, dimethylaminomethyl,2-dimethylaminoethyl, pyrrolidin-l-ylmethyl, 2-pyiTolidin-l-ylethyl, piperidinomethyl, 2-piperidinoethyl, morpholinomethyl, 2-morpholinoethyl, piperazin-1-ylmethyl, 2-piperazin-l-ylethyl, 4-methylpiperazin-1-ylmethyl and 2-(4-methylpiperazin-l-yl)ethyl; m is 1 and R1is hydrogen or methoxy;and Q is phenyl which optionally bears 1,2 or 3 substituents selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl and methoxy;or a pharmaceutically-acceptable acid-addition salt thereof.A further preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link;Q1is 2-thienyl which optionally bears a substituent selected from aminomethyl, morpholinomethyl and 2-morpholinoethyl;m is 1 and R1is hydrogen or methoxy;and Q is phenyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo and methyl;or a pharmaceutically-acceptable acid-addition salt thereof.A further specific especially preferred compound of the invention is the quinazoline derivative of the formula I:4-(3-chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline;or a pharmaceutically-acceptable acid-addition salt thereof.A further preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link or a group of the formula O;Q1is phenyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo, amino, cyano, nitro, aminomethyl, methylaminomethyl, dimethylaminomethyl, diethylaminomethyl, pyrrolidin-l-ylmethyl, piperidinomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-methylpiperazin-1-ylmethyl;m is 1 and R1is hydrogen or methoxy; andQ is phenyl which optionally bears 1, 2 or 3 substituents selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl and methoxy, or Q is a group of the formula IIwherein X2is a group of the formula OCH2, Q3is 2-pyridyl, n is 1 and R4is hydrogen, fluoro, chloro or methyl;or a pharmaceutically-acceptable acid-addition sal; thereof.A further preferred compound of the invention is a quinazoline derivative of the formula I wherein X1is a direct link or a group of the formula O;Q1is phenyl which optionally bears 1 or 2 substituents selected from amino, aminomethyl, diethylaminomethyl, pyrrolidin-l-ylmethyl, piperidinomethyl and morpholinomethyl; m is 1 and R1is hydrogen; andQ is phenyl which optionally bears 1 or 2 substituents selected from fluoro, chloro and methyl;or a pharmaceutically-acceptable acid-addition sal t thereof.A further specific especially preferred compound of the invention is the quinazoline derivative of the formula I:4-(3-methylanilino)-6-phenylquinazoline,6-(4-aminomethylphenyl)-4-(3-chloro-4-fluoroanii ino)quinazoline,6-(4-aminophenoxy)-4-(3-chloro-4-fluoroanilino)quinazoline,6-(4-aminomethylphenoxy)-4-(3-chloro-4-fluoroamilino)quinazoline or4-(3-chloro-4-fluoroanilino)-6-(4-morpholinometf.ylphenoxy)quinazoline;or a pharmaceutically-acceptable acid-addition sal t thereof.A quinazoline derivative of the formula 1, or a pharmaceutically-acceptable salt thereof, may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Suitable processes include, for example, those illustrated in European Patent Applications Nos. 0520722, 0566226, 0602851, 0635507 and 0635498, and International Patent Applications WO 96 / 15118 and WO 96 / 16960. Such processes, when used to prepare a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, are provided as a further feature of the invention and are illustrated by the following representative examples in which, unless otherwise stated, X , Q , m, R and Q have any of the meanings defined hereinbefore for a quinazoline derivative of the formula I. Necessary-22starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.(a) The reaction, conveniently in the presence of a suitable base, of a quinazoline of the formula IIIwherein Z is a displaceable group, with an aniline of the formula Q -NH2.A suitable base is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-'7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal hydride, for example sodium hydride.A suitable displaceable group Z is, for ex ample, a halogeno, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy or toluene-4-sulphonyloxy group. The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as N,N-dimethylformamide,N,N-dimethylacetamide, N-methylpyrrolidin-2-one or dimethylsulphoxide. The reaction is conveniently carried out at a temperature in the range, for example, 10 to 250°C, preferably in the range 40 to 80°C.The quinazoline derivative of the formul a I may be obtained from this process in the form of the free base or alternatively it may be obtained in the form of a salt with the acid of the formula H-Z wherein Z has the meaning defined hereinbefore. When it is desired to obtain the free base from the salt, the salt may be treated with a suitable base, for example, an-23 organic amine base such as, for example, pyridine, 2,6-lutidine, collidine,4-dimethylaminopyridine, triethylamine, morpholine, N-methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide.(b) For the preparation of those compounds of the formula I wherein X1is a direct link, the reaction, conveniently in the presence of a suitable catalyst, of a quinazoline of the formula IVQ2NHwherein Z is a displaceable group as defined hereinbefore, with an organoboron reagent of the112 12 formula Q -B(L )(L ) wherein each L and L , which may be the same or different, is a suitable ligand.A suitable value for the ligands L and L which are present on the boron atom include, for example, a hydroxy, (l-4C)alkoxy or (l-6C)alkyl ligand, for example a hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methyl, ethyl, propyl, isopropyl or butyl • •12* ligand. Alternatively the ligands L and L may be linked such that, together with the boron atom to which they are attached, they form a ring. For example, L and L together may define an oxy-(2-4C)alkylene-oxy group, for example an oxyethyleneoxy or oxytrimethyleneoxy group such that, together with the boron atom to which they are attached, they form a cyclic boronic acid ester group. Partic ilarly suitable organoboron reagents include, for example, compounds of the formulae ( / -B(OH)2, Q'-B(OPrj2and Q*-B(Et)2.A suitable catalyst for the reaction includes, for example, a metallic catalyst such as a palladium(O), palladium(II), nickel(O) or nickel(n) catalyst, for example tetrakis(triphenylphosphine)palladium(0), palladiu;n(II) chloride, palladium(II) bromide, bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)nickel(0), nickel(II)~chloride, nickel(II) bromide or bis(triphenylphosphine)nickel(II) chloride. In-24addition a free radical initiator may conveniently be added, for example an azo compound such as azo(bisisobutyronitrile).The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an ether such as tetrahydrofuran, 1,4-dioxan or 1,2-dimethoxyethane, an aromatic solvent such as benzene, toluene or xylene, or an alcohol such as methanol or ethanol, and the reaction is conveniently carried out at a temperature in the range, for example 10 to 250°C, preferably in the range 60 to 120°C.Organoboron reagents of the formula Q -B(L )(L ) may be obtained by standard procedures of organic chemistry which are within the ordinary skill of an organic chemist, for example by the reaction of an organometallic compound of the formula Q’-M, wherein M is, for example, lithium or the magnesium halide port ion of a Grignard reagent, with an organoboron compound of the formula Z-B(L )(L ) wherein Z is a displaceable group as defined hereinbefore. Preferably the compound of the formula Z-B(L )(L ) is, for example, boric acid or a tri-(l-4C)alkyl borate such as tri-isopropyl borate.In an alternative procedure the organobor on compound of the formulaQ -B(L )(L ) may be replaced with an organometal lic compound of the formula Q -M wherein M is a metal atom or a metallic group (i.e. a metal atom bearing suitable ligands). Suitable values for the metal atom include, for example, lithium and copper. Suitable values for the metallic group include, for example, groups which contain a tin, silicon, zirconium, aluminium, magnesium or mercury atom. Suitable ligands within such a metallic group include, for example, hydroxy groups, (l-6C)alkyl groups such as methyl, ethyl, propyl, isopropyl and butyl groups, halogeno groups such as chloro, bromo and iodo groups, and (l-6C)alkoxy groups such as methoxy, ethoxy, pre poxy, isopropoxy and butoxy groups. A particular organometallic compound of the formula Q’-M is, for example, an organotin compound such as a compound of the formula Q*-SnBu3, an organosilicon compound such as a compound of the formula Q’-Si(Me)F2, an organozirconium compound such as a compound of the formula Q'-ZrCl3, an organoaluminium compound such as a compound of the formula Q*-AlEt2, an organomagnesium compound such as a compound of the formula Q’-MgBr, or an organomercury compound such as a compound of the formula Q’-HgBr.(c) For the preparation of those compounds of the formula I wherein X1is a direct link, the reaction, conveniently in the presence of a suit able catalyst as defined hereinbefore, of a quinazoline of the formula V-25Q2I 2 · wherein each of L and L , which may be the same, or different, is a suitable ligand as defined hereinbefore, with a compound of the formula Q*-Z wherein Z is a displaceable group as defined hereinbefore.The reaction is conveniently carried out in a suitable inert solvent or diluent and at a suitable temperature in an analogous manner to the conditions described in paragraph (b) hereinbefore.The quinazoline of the formula V may conveniently be obtained by analogous procedures to those described hereinbefore for the preparation of the organoboron reagent of the formula Q'-B^'jfL2).(d) For the production of those compounds cf the formula I wherein X1is a group of the formula N(R )CO or N(R )SO2, the acylation of an amine of the formula VIQ2with a carboxylic acid of the formula Q!-CO2H, oi a reactive derivative thereof, or a sulphonic acid of the formula Q’-SO2OH, or a reactive derivative thereof, as appropriate.A suitable reactive derivative of a carboxylic acid of the formula Q*-CO2H is, for example, an acyl halide, for example an acyl chloride formed by the reaction of the acid and an inorganic acid chloride, for example thionyl chloride; a mixed anhydride, for example an anhydride formed by the reaction of the acid and a chloroformate such as isobutyl chloroformate; an active ester, for example an ester formed by the reaction of the acid and a phenol such-as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate or an alcohol such as methanol, ethanol, isopropanol, butanol or N-hydroxybenzotriazole; an acyl azide, for example an azide formed by the reaction of the acid and azide such as-26diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cy anide; or the product of the reaction of the acid and a carbodiimide such as dicyclohexylcarbodiimide. Analogously suitable reactive derivatives of the sulphonic acid of the formula QI-SO2OH may be obtained.The reaction is conveniently carried out i n a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 0 to 120°C, preferably at or near ambient temperature.(e) For the production of those compounds of the formula I wherein X1is a group of the formula OC(R2)2, SC(R2)2 or N(R2)C(R2)2, the alkylation, conveniently in the presence of a suitable base as defined hereinbefore, of an appropriate phenol, thiophenol or aniline with an alkylating agent of the formula Z-C(R )2-Q wherein Z is a displaceable group as defined hereinbefore.The reaction is conveniently carried out in a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 10 to 150°C, preferably at or near 80°C.(f) For the production of those compound of the formula I wherein X1is a group of the formula C(R2)2O, C(R2)2S or C(R2)2N(R2), the alkylation, conveniently in the presence of a suitable base as defined hereinbefore, of the appropriate phenol of the formula HO-Q1, thiophenol of the formula HS-Q or aniline of the formula R NH-Q , with an alkylating agent of the formula VIIQ2Xwherein Z is a displaceable group as defined hereinbefore.The reaction is conveniently carried out in a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 0 to 150°C, preferably in the range 20 to 70°C.(g) For the production of those compounds of the formula I which possess an aminomethyl substituent or wherein X is a group of the formula N(R )CH2or CH2N(R ), the-27reduction of a compound of the formula I which possesses a cyano substituent or wherein X1is a group of the formula N(R2)CO or CON(R2) as appropriate.The reduction may be carried out by any of the many procedures known in the art for such transformations. A suitable reducing agent is, for example, an alkali metal aluminium hydride such as lithium aluminium hydride.The reduction is conveniently carried out in a suitable inert solvent or diluent such as diethyl ether or tetrahydrofuran and at a temperature in the range, for example, to 80°C, preferably in the range 15 to 50°C.(h) For the production of those compounds of the formula I which possess an amino substituent, the reduction of a compound of the formula I which possesses a nitro substituent.The reduction may conveniently be carried out by any of the many procedures known for such a transformation. The reduction may be carrried out, for example, by the hydrogenation of a solution of the nitro compound in an inert solvent or diluent as defined hereinbefore in the presence of a suitable metal calalyst such as palladium or platinum. A further suitable reducing agent is, for example, an Eictivated metal such as activated iron (produced by washing iron powder with a dilute solution of an acid such as hydrochloric acid). Thus, for example, the reduction may be carried out by heating a mixture of the nitro compound and the activated metal in a suitable solvent or diluent such as a mixture of water and an alcohol, for example, methanol or ethanol, to a temperature in the range, for example, 50 to 150°C, conveniently at or near 70°C.(i) For the production of those compounds cf the formula I wherein X1is a group of the formula NHCH(R ), the reductive amination of a keto compound of the formula R2-CO-Q!with an amine of the formula VIIIQ2Xmay be employed. A suitable reducing agent is, for example, a hydride reducting agent, for-28example an alkali metal aluminium hydride such as lithium aluminium hydride or, preferably, an alkali metal borohydride such as sodium borohydride, sodium cyanoborohydride, sodium triethylborohydride, sodium trimethoxyborohydride and sodium triacetoxyborohydride. The reaction is convenient] y performed in a suitable inert solvent or diluent, for example tetrahydrofiiran and diethyl ether for the more powerful reducing agents such as lithium aluminium hydride, and, for example, methylene chloride or a pro tic solvent such as methanol and ethanol for the less powerful reducing agents such as sodium triacetoxyborohydride and sodium cyanoborohydride. The reaction is performed at a temperature in the range, for example, 10 to 80°C, conveniently at or near ambient temperature.(j) For the production of those compounds of the formula I wherein X1is a group of the formula O, S or N(R ), the coupling, conveniently in the presence of a suitable base as defined hereinbefore, of an appropriate phenol, thiophenol or aniline with a compound of the formula Z-Q1wherein Z is a displaceable group as defined hereinbefore.Conveniently the reaction may be performed in the presence of a suitable catalyst, for example a metallic catalyst such as a palladium (0) or copper(I) catalyst, for example tetrakis(triphenylphosphine)palladium(0), cuprous chloride or cuprous bromide.The coupling reaction is conveniently performed in a suitable inert solvent or diluent as defined hereinbefore, preferably in N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-onc, dimethylsulphoxide or acetone, and at a temperature in the range, for example, 10 to 150°C , conveniently at or near 100°C.When a pharmaceutically-acceptable salt, of a quinazoline derivative of the formula I is required, for example a mono- or di-acid-addit .on salt, it may be obtained, for example, by reaction of said compound with, for example, a suitable acid using a conventional procedure.As stated hereinbefore the quinazoline derivative defined in the present invention possesses anti-proliferative activity such as anti-cancer activity which is believed to arise from the Class I receptor tyrosine kinase inhibitory activity of the compound. These properties may be assessed, for example, using one or more cf the procedures set out below:(a) An in vitro assay which determines the ability of a test compound to inhibit the enzyme EGF receptor tyrosine kinase. Receptor tyrosine kinase was obtained in partially purified form from A-431 cells (derived from human vulval carcinoma) by the procedures described below which are related to those described by Carpenter et al., J, Biol. Chem., 1979,-29254, 4884, Cohen et ah, J, Biol. Chem.. 1982, 257. 1523 and by Braun et ah, J. Biol. Chem.. 1984, 259. 2051.A-431 cells were grown to confluence using Dulbecco’s modified Eagle’s medium DMEM) containing 5% fetal calf serum (FCS). Trie obtained cells were homogenised in a hypotonic borate / EDTA buffer at pH 10.1. The homogenate was centrifuged at 400 g for 10 minutes at 0-4°C. The supernatant was centrifuged at 25,000 g for 30 minutes at 0-4°C. The pelleted material was suspended in 30 mM Hepes buffer at pH 7.4 containing 5% glycerol, mM benzamidine and 1% Triton X-100, stirred for 1 hour at 0-4°C, and recentrifuged at 100,000 g for 1 hour at 0-4°C. The supernatant, containing solubilised receptor tyrosine kinase, was stored in liquid nitrogen.For test purposes 40 μΐ of the enzyme solution so obtained was added to a mixture of 400 μΐ of a mixture of 150 mM Hepes buffer at pH 7.4, 500 μΜ sodium ortho vanadate, 0.1% Triton X-100, 10% glycerol, 200 μΐ water, 80 μΐ of 25 mM DTT and 80 μΐ of a mixture of12.5 mM manganese chloride, 125 mM magnesium chloride and distilled water. There was thus obtained the test enzyme solution.Each test compound was dissolved in dirnethylsulphoxide (DMSO) to give a 50 mM solution which was diluted with 40 mM Hepes buffer containing 0.1% Triton X-100, 10% glycerol and 10% DMSO to give a 500 μΜ solution. Equal volumes of this solution and a solution of epidermal growth factor (EGF; 20 pg / ml) were mixed.[γ-32ρ]ΑΤΡ (3000 Ci / mM, 250 pCi) was diluted to a volume of 2 ml by the addition of a solution of ATP (100 μΜ) in distilled water. z\n equal volume of a 4 mg / ml solution of the peptide Arg-Arg-Leu-Ile-Glu-Asp-Ala-Glu-Tyr-Ala-Ala-Arg-Gly in a mixture of 40 mM Hepes buffer at pH 7.4, 0.1% Triton X-100 and 1C% glycerol was added.The test compound / EGF mixture solution (5 μΐ) was added to the test enzyme solution (10 μΐ) and the mixture was incubated at 0-4°C for 30 minutes. The ATP / peptide mixture (10 μΐ) was added and the mixture was incubated at 25°C for 10 minutes. The phosphorylation reaction was terminated by the addition of 5% trichloroacetic acid (40 μΐ) and bovine serum albumin (BSA; 1 mg / ml, 5 μΐ). The mixture was allowed to stand at 4°C for 30 minutes and then centrifuged. An aliquot (40 μΐ) of the supernatant was placed onto a strip ofJVhatman p 81 phosphocellulose paper. The strip was washed in 75 mM phosphoric acid (4x10 ml) and blotted dry. Radioactivity present in the filter paper was measured using a liquid scintillation counter (Sequence A). The reaction sequence was repeated in the-30absence of the EGF (Sequence B) and again in the absence of the test compound (Sequence C).Receptor tyrosine kinase inhibition was calculated as follows:100-(A-B) % Inhibition =___χ 100C -BThe extent of inhibition was then determined at a range of concentrations of test compound to give an IC50value.(b) An in vitro assay which determines the ability of a test compound to inhibit the EGF-stimulated growth of the human naso-pharyngeal cancer cell line KB.KB cells were seeded into wells at a density of 1 x 10^ - 1.5 χ 10^ cells per well and grown for 24 hours in DMEM supplemented with 5% FCS (charcoal-stripped). Cell growth was determined after, incubation for 3 days by the extent of metabolism of MTT tetrazolium dye to furnish a bluish colour. Cell growth was then determined in the presence of EGF (10 ng / ml) or in the presence of EGF (10 ng / ml) and a test compound at a range of concentrations. An IC50value could then be calculated.(c) An in vivo assay in a group of male rats which determines the ability of a test compound (usually administered orally as a ball-milled suspension in 0.5% polysorbate) to inhibit the stimulation of liver hepatocyte growth caused by the administration of the growth factor TGFa (400 pg / kg subcutaneously, usually dosed twice, 3 and 7 hours respectively after the administration of the test compound).In a control group of rats, the administration of TGFa causes on average a 5-fold stimulation of liver hepatocyte growth.Cell-growth in the control and test animals is determined as follows:On the morning of the day after the dosing of the test compound (or 0.5% polysorbate in the control group), the animals are dosed with bromodeoxyuridine (BrdU; 100 mg / kg intraperitoneally). The animals are killed four hours later and the livers are excised. Slices are cut from each liver and the uptake of BrdU is determined by a conventional immunohistochemical technique similar to that described on pages 267 and 268 of an article by Goldsworthy et al. in Chemically Induced Cell Proliferation: Implications for Risk Assessment, Wiley-Liss Inc., 1991, pages 253-284. Further tests were carried out using a range of doses of the test compounds to allow the calculation of an approximate ED50value-31 for the inhibition of liver hepatocyte proliferation £ts determined by inhibition of the uptake of BrdU.(d) An in-vivo assay in a group of athymic nude mice (strain ONU:Alpk) which determines the ability of a test compound (usually administered orally as a ball-milled suspension in 0.5% polysorbate) to inhibit the growth of xenografts of the human vulval epidermoid carcinoma cell line A-431.A-431 cells were maintained in culture in DMEM supplemented with 5% FCS and 2mM glutamine. Freshly cultured cells were harvested by trypsinization and injected subcutaneously (10 million cells / 0.1 ml / mouse) into both flanks of a number of donor nude mice. When sufficient tumour material was available (after approximately 9 to 14 days), fragments of tumour tissue were transplanted into he flanks of recipient nude mice (test day 0). Generally, on the seventh day after transplantation (test day 7) groups of 7 to 10 mice with similar-sized tumours were selected and dosing of the test compound was commenced. Once-daily dosing of test compound was continued for a total of 13 days (test days 7 to 19 inclusive). In some studies the dosing of the test compound was continued beyond test day 19, for example to test day 26. In each case, on the following day the animals were killed and final tumour volume was calculated from measure ments of the length and width of the tumours. Results were calculated as a percentage inhibition of tumour volume relative to untreated controls.Although the pharmacological properties of the compounds of the formula I vary with structural change as expected, in general activity possessed by compounds of the formula I may be demonstrated at the following concentrations or doses in one or more of the above tests (a), (b), (c) and (d):Test(a):- IC50in the range, for example, 0.01-1 μΜ;Test (b):- IC50in the range, for example, 0.1-10 μΜ;Test (c):- ED50in the range, for example, 1-100 mg / kg;Test (d):- 20 to 70% inhibition of tumour volume from a daily dose in the range, for example, 50 to 400 mg / kg.Thus, by way of example, the compound 4-(3-chloro-4-fluoroanilino)-6-[5-(2morpholinoethyl)thien-2-yl]quinazoline has an IC;i0of 0.04 μΜ in Test (a), an IC50of 0.19 μΜ in Test (b) and gives 64% inhibition in Test (cl) at a dosage of 50 mg / kg / day.-32According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including; intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.In general the above compositions may be prepared in a conventional manner using conventional excipients.The quinazoline derivative will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg / kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-100 mg / kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.According to a further aspect of the present invention there is provided a quinazoline derivative of the formula I as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.We have now found that the compounds of the present invention possess anti-proliferative properties which are believed to arise from their Class I (EGF type) receptor tyrosine kinase inhibitory activity. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases c r medical conditions mediated alone or in part by Class I receptor tyrosine kinase enzymes, i .e. the compounds may be used to produce a Class I receptor tyrosine kinase inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for treating the proliferation of malignant cells characterised by inhibition of Class I receptor tyrosine kinase enzymes, i.e. the compounds may be used to produce an anti-proliferative effect mediated alone or in part by the inhibition of Class I receptor tyrosine kinase. Accordingly the compounds of the present invention are expected to be useful in the treatment of cancer by-33 providing an anti-proliferative effect, particularly in the treatment of Class I receptor tyrosine kinase sensitive cancers such as cancers of the breast, lung, colon, rectum, stomach, prostate, bladder, pancreas and ovary. The compounds of the present invention are also expected to be useful in the treatment of other cell-proliferation diseases such as psoriasis, benign prostatic hypertrophy, atherosclerosis and restenosis.Thus according to this aspect of the invention there is provided the use of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.According to a further feature of this aspect of the invention there is provided a method for producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a quinazoline derivative as defined immediately above.As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the sev erity of the illness being treated. A unit dose in the range, for example, 1-100 mg / kg, preferably 1-50 mg / kg is envisaged.The anti-proliferative treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinazoline derivative of the invention, conventional radiotherapy or one or more other anti-tumour substances, for example cytotoxic or cytostatic anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine, vindesine and v inorelbine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; antimetabolites, for example 5-fluorouracil, tegafur, methotrexate, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred antimetabolites disclosed in European Patent Application No. 239362 such as N-{5 - [N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-y Imethy l)-N-methylamino]-2thenoyl }-L-glutamic acid; intercalating antibiotics, for example adriamycin, mitomycin and bleomycin; enzymes, for example asparaginase; topoisomerase inhibitors, for example etoposide and camptothecin; biological response modifiers, for example interferon; and anti-hormones, for example antioestrogens such as tamoxifen, for example antiandrogens such as 4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'(trifluoromethyl)propionanilide or, for example LHRH antagonists or LHRH agonists such as-34goserelin, leuprorelin or buserelin and hormone synthesis inhibitors, for example aromatase inhibitors such as those disclosed in European Pate nt Application No. 0296749, for example 2,2’-[5-(lH-l,2,4-triazol-l-ylmethyl)-l,3-phenylerie]bis(2-methylpropionitrile), and, for example, inhibitors of 5a-reductase such as 17p-(N-tert-butylcarbamoyl)-4-aza-5a-androst5 l-en-3-one. Such conjoint treatment may be achie ved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. According to this aspect of the invention there is provided a pharmaceutical product comprising a quinazoline derivative of the formula I as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.As stated above the quinazoline derivative defined in the present invention is an effective anti-cancer agent, which property is believed to arise from its Class I (EGF type) receptor tyrosine kinase inhibitory properties. Such a quinazoline derivative of the invention is expected to possess a wide range of anti-cancer properties as Class I receptor tyrosine kinases have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach, prostate, bladder, pancreas and ovarian cancer. Thus it is expected that a quinazoline derivative of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a quinazoline derivative of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, prostate and pancreas.It is further expected that a quinazoline derivative of the present invention will possess activity against other cell-proliferation diseases such as psoriasis, benign prostatic hypertrophy, atherosclerosis and restenosis.It is also to be expected that a quinazoline derivative of the invention will be useful in the treatment of additional disorders of cellular growth in which aberrant cell signalling by way of receptor tyrosine kinase enzymes, including- as yet unidentified receptor tyrosine kinase enzymes, are involved. Such disorders include, for example, inflammation, angiogenesis, vascular restenosis, immunological disorders, pancreatitis, kidney disease and blastocyte maturation and implantation.The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:-35(i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;(ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon;(iii) column chromatography (by the flas / ι procedure) and medium pressure liquid chromatography (MPLC) were performed on Merck Kieselgel silica (Art. 9385) or Merck Lichroprep RP-18 (Art. 9303) reversed-phase silica obtained from E. Merck, Darmstadt, Germany;(iv) yields are given for illustration only and are not necessarily the maximum attainable;(v) melting points were determined using a Mettler SP62 automatic melting point apparatus, an oil-bath apparatus or a Koffler hot plate apparatus.(vi) the structures of the end-products of the formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multilicities are shown as follows: s, singlet; d, doublet; t, triplet; rr., multiplet, unless otherwise stated endproducts of the formula I were dissolved in CD3SOCD3for the determination of NMR values.(vii) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), infra-red (IR) or NMR analysis;(viii) the following abbreviations have been used:DMF Ν,Ν-dimethylformamide;DMA N,N-dimethylacetamide;NMP N-methylpyrrolidin-2-one;THF tetrahydrofiiran;DME 1,2-dimethoxyethane.-36Example 1Tetrakis(triphenylphosphine)palladium(0) (0.04 g) was added to a stirred mixture of 6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride salt (0.25 g), a saturated aqueous sodium bicarbonate solution (1.5 ml), di-isopropyl 4-cyanophenylboronate and DME (10 ml). The resultant mixture was stirred and heated to reflux for 3 hours. The mixture was cooled to ambient temperature. An aqueous sodium hydroxide solution (5M, 2 ml) and water were added in turn and the resultant precipitate was isolated by filtration, dried and purified by column chromatography using a 10:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(4-cyanophenyl)quinazoline (0.05 g, 18%), m.p. >250°C;NMR Spectrum: 7.5 (t, 1H), 7.85 (m, 1H), 7.9 (d, l.H), 8.0-8.15 (m, 4H), 8.2 (m, 1H), 8.55 (m, 1H), 8.65 (s, 1H), 8.9 (d, 1H), 10.0 (broad s, H I);Elemental Analysis: Found C, 66.1; H, 3.3; N, 14.3;C21H12C1FN40.35H2O requires C, 66.2; H, 3.4; N, 14.7%.The 6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride salt used as a starting material was obtained as follows:A mixture of 5-bromoanthranilic acid (15.2 g) and formamide (20 ml) was heated to 140°C for 2 hours and then to 190°C for 2 hours. The mixture was cooled to ambient temperature. Methanol (20 ml) was added and the mixture was heated to reflux for 5 minutesWater (150 ml) was added and the mixture was cooled to ambient temperature. The precipitate was washed with water and dried. There was thus obtained 6-bromo-3,4dihydroquinazolin-4-one (14.1 g).A mixture of a portion (2.85 g) of the material so obtained, thionyl chloride (30 ml) and DMF (4 drops) was stirred and heated to reflux for 3 hours. The mixture was evaporated to give 6-bromo-4-chloroquinazoline which was used without further purification.A mixture of the material so obtained, 3-chloro-4-fluoroaniline (1.85 g) and isopropanol (30 ml) was stirred and heated to reflux for 3 hours. The mixture was allowed to cool to ambient temperature and the solid was isolated, washed in turn with isopropanol and diethyl ether and dried. There was thus obtained 6 bromo-4-(3-chloro-430 fluoroanilino)quinazoline hydrochloride salt, (2.65 g);-37NMR Spectrum: 7.53 (t, IH), 7.8 (m, IH), 7.94 (d, IH), 8.09 (m, IH), 8.26 (m, IH), 8.98 (s, IH), 9.3 (d, IH);Elemental Analysis: Found C, 43.2; H, 2.4; N, 10.6;Ci4H8BrClFN31HC1 requires C, 43.2; H, 2.3; N, 10.8%.The di-isopropyl 4-cyanophenylboronate used as a starting material was obtained as follows :n-Butyllithium (1.6M in hexane, 1 ml) was added dropwise to a stirred mixture of 4-bromobenzonitrile (0.254 g), tri-isopropyl borate (0.4 ml) and THF (10 ml) which had been colled to -78°C. The resultant mixture was stirred and allowed to warm to ambient temperature. The mixture was evaporated to give the required starting material which was used without further purification.Example 2Tetrakis(triphenylphosphine)palladium(0) (0.019 g) and a solution of phenylboronic acid (0.083 g) in ethanol (1 ml) were added in turn ito a stirred mixture of 6-bromo-4-(3methylanilino)quinazoline hydrochloride salt (European Patent Application No. 0520722, Example 9 thereof, 0.245 g), a saturated aqueous sodium carbonate solution (0.4 ml) and toluene (1.2 ml). The resultant mixture was stirred and heated to reflux for 6 hours. The mixture was cooled to ambient temperature and partitioned between methylene chloride and water. The organic phase was washed with water, dried (MgSO4) and evaporated. The residue was purified by column chromatography using a 4:1 mixture of methylene chloride and ethyl acetate as eluent. There was thus obtained 4-(3-methylanilino)-6-phenylquinazoline (0.159 g), m.p. 207-209°C;NMR Spectrum: 2.3 (s, 3H), 6.95 (d, IH), 7.3 (t, IH), 7.4-7.9 (m, 8H), 8.2 (m, IH), 8.6 (s, IH), 8.85 (m, IH), 9.8 (broad s, IH);Elemental Analysis: Found C, 78.8; H, 5.5; N, 12.7;C2iH17N30.5H2O requires C, 78.7; H, 5.6; N, 13.140.Example 3Lithium aluminium hydride (1M in diethyl ether, 20 ml) was added dropwise to a stirred mixture of 4-(3-chloro-4-fluoroanilino)-6-(4-cyanophenyl)quinazoline (0.706 g), diethyl ether (25 ml) and THF (25 ml) and the resultant mixture was stirred at ambient-38temperature for 16 hours. The mixture was cooled to 0°C. Water (2 ml), 5M aqueous sodium hydroxide solution (2 ml) and water (6 ml) were added in turn and the mixture was allowed to warm to ambient temperature. The mixture was fil tered and the filtrate was evaporated. The residue was purified by column chromatography using a 10:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 6-(4-aminomethylphenyl)-4-(3-chloro-4fluoroanilino)quinazoline (0.409 g);NMR Spectrum: 4.0 (s, 2H), 7.4 (t, 1H), 7.6 (d, 2H), 7.8-8.0 (m, 4H), 8.2 (m, 2H), 8.6 (s, 1H), 8.9 (s, 1H), 10.1 (broads, 1H).Example 4Tetrakis(triphenylphosphine)palladium(0} (0.05 g) and a saturated aqueous sodium bicarbonate solution (5 ml) were added in turn to a stirred mixture of 6-bromo-4-(3-chloro-4fluoroanilino)quinazoline hydrochloride salt (0.35 g), 3-furylboronic acid (J. Het. Chem., 1975, 195; 0.208 g) and DME (15 ml). The resultant mixture was stirred and heated to reflux for 2 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic phase was washed with water and with brine, dried (MgSO4) and evaporated. The residue was purified by column chromatography using initially methylene chloride and then increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro-4-f luoroanilino)-6-(3-furyl)quinazoline;NMR Spectrum: 7.16 (m, 1H), 7.48 (t, 1H), 7.82 (cf, 1H), 7.85 (m, 2H), 8.16 (m, 1H), 8.18 (m, 1H), 8.35 (d, 1H), 8.61 (s, 1H), 8.7 (d, 1H), 9.88 (s, 1H);Elemental Analysis: Found C, 62.8; H, 3.4; N, 10.8;ClgH,,ClFN3O 0.25H2O requires C, 62.8; H, 3.3; N, 12.2%.Example 5Tetrakis(triphenylphosphine)palladium(Oj (0.05 g) was added to a stirred mixture of 6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride salt (0.613 g), a saturated aqueous sodium bicarbonate solution (10 ml), di-isopropyl 2-furylboronate and DME (20 ml). The resultant mixture was stirred and heated to reflux for 1.5 hours. The mixture was cooled to ambient temperature. An aqueous sodium hydroxide solution (5M, 10 ml) and water were added in turn. The resultant precipitate was isolated, washed with a small amount of-39methylene chloride and dried. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(2furyl)quinazoline (0.54 g), m.p. 232-234°C;NMR Spectrum: 6.7 (m, IH), 7.15 (d, IH), 7.4 (t, IH), 7.8 (m, 3H), 8.2 (m, 2H), 8.55 (s, IH), 8.8 (d, IH), 10.0 (broad s, IH);Elemental Analysis: Found C, 57.8; H, 3.6; N, 10.5';C18HhC1FN3O 1.9H2O requires C, 57.8; H, 4.0; N, 11.2%.The di-isopropyl 2-furylboronate used as a starting material was obtained as follows :n-Butyllithium (1.6M in hexane, 2.75 ml) was added dropwise to a stirred solution of furan (0.25 g) in THF (10 ml) which had been cooled to 0°C. The resultant mixture was stirred at ambient temperature for 20 minutes. The mixture was cooled to -78°C and triisopropyl borate (1 ml) was added dropwise. The mixture was allowed to warm to ambient temperature and was stirred for 2 hours. The mixture was evaporated to give the required starting material which was used without further purification.Example 6Using an analogous procedure to that described in Example 5 except that the reaction mixture was heated to reflux for 3 hours, 6 -bromo-4-(3-chloro-4fluoroanilino)quinazoline hydrochloride salt was reacted with di-isopropyl 2-thienylboronate to give 4-(3-chloro-4-fluoroanilino)-6-(2-thienyl)quinazoline in 36% yield, m.p. 205-208°C; NMR Spectrum: 7.2 (m, IH), 7.4 (t, IH), 7.7 (m, Zii), 7.8 (m, 2H), 8.15 (m, 2H), 8.55 (s, IH), 8.75 (d, IH), 10.0 (broad s, IH);Elemental Analysis: Found C, 58.6; H, 3.1; N, 11.3;C18H11C1FN3S 0.75H2O requires C, 58.5; H, 3.4; N, 11.4%.The di-isopropyl 2-thienylboronate used as a starting material was obtained as follows :n-Butyllithium (1.6M in hexane, 2 ml) was added dropwise to a stirred solution of 2-bromothiophene (0.515 g) in THF (6 ml) which had been cooled to -78°C. Tri-isopropyl borate (0.75 ml) was added dropwise and the resultant mixture was stirred and allowed to warm to ambient temperature. The mixture was evaporated to give the required starting material which was used without further purification.-40Example 7Using an analogous procedure to that described in Example 5 except that the reaction mixture was heated to reflux for 2 hours, 6-bromo-4-(3-chloro-4fluoroanilino)quinazoline hydrochloride salt was reacted with di-isopropyl 3-thienylboronate to give 4-(3-chloro-4-fluoroanilino)-6-(3-thienyl)quinazoline in 51% yield, m.p. 195-197°C; NMR Spectrum: 7.5 (t, IH), 7.7-7.9 (m, 4H), 8.05 (m, IH), 8.2 (m, IH), 8.25 (m, IH), 8.6 (s, IH), 8.8 (d, IH), 9.9 (broad s, IH);Elemental Analysis: Found C, 57.8; H, 3.3; N, 10.6;C18H,,C1FN3S 1.15H2O requires C, 57.4; H, 3.6; Ν, 11.2%.The di-isopropyl 3-thienylboronate used as a starting material was obtained by the reaction of 3-bromothiophene and tri-isopropyl borate using an analogous procedure to that described in the portion of Example 6 which is concerned with the preparation of starting materials.Example 8Using an analogous procedure to that described in Example 5 except that the reaction mixture was heated to reflux for 4 hours, 6 -bromo-4-(3-chloro-4fluoroanilino)quinazoline hydrochloride salt was reacted with di-isopropyl 5-(2morpholinoethyl)thien-2-ylboronate. The reaction mixture was cooled to ambient temperature and partitioned between methylene chloride and water. The organic phase was washed with brine, dried (MgSO4) and evaporated. The residue was triturated under a mixture of hexane and ethyl acetate to give 4-(3-chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2yljquinazoline in 27% yield;NMR Spectrum: 2.6-2.7 (t, 2H), 3.0 (t, 2H), 3.65 (t, 4H), 7.0 (d, IH), 7.45 (t, IH), 7.55 (d, IH), 7.8 (m, 2H), 8.1 (m, IH), 8.2 (m, IH), 8.6 (s, IH), 8.75 (d, IH), 9.95 (broad s, IH); Elemental Analysis: Found C, 59.0; H, 4.9; Ν, 11.3;C24H22C1FN4OS 1H2O requires C, 59.2; H, 5.0; Ν, 11.5%.The di-isopropyl 5-(2-morpholinoethyl)thien-2-ylboronate used as a starting material was obtained as follows:2-(2-Thienyl)acetyl chloride (16 g) was added slowly to a stirred mixture of morpholine (17.5 ml) and methylene chloride (150 ml). A further portion (5 ml) of morpholine was added and the mixture was stirred a: ambient temperature for 4 hours. The-41 reaction mixture was washed in turn with 2M aqueous hydrochloric acid, a saturated aqueous sodium bicarbonate solution and brine. The organic phase was dried and evaporated. The residue was triturated under a mixture of hexane and diethyl ether to give N-[2-(2thienyl)acetyl]morpholine (20.9 g).Lithium aluminium hydride (IM in diethyl ether, 28.3 ml) was added slowly to a stirred solution of N-[2-(2-thienyl)acetyl]morpholime (3 g) in THF (100 ml). The resultant mixture was heated to 45°C for 30 minutes. A 2M aqueous hydrochloric acid solution was added dropwise to destroy the excess of reducing agent and the mixture was partitioned between methylene chloride and a 2M aqueous sodium hydroxide solution. The organic phase was washed with brine, dried (MgSO4) and evaporated to give 2-(2-morpholinoethyl)thiophene (1.7 g).A portion (1.22 g) of the material so obtained was dissolved in THF (75 ml) and the solution was cooled to -78°C. n-Butyllithium (1.6M in hexane, 3.86 ml) was added dropwise and the mixture was stirred at -78°C for 30 minutes. A solution of tri-isopropyl borate (1.16 ml) in THF (25 ml) was added and the reaction mixture was then allowed to warm to ambient temperature. The mixture was evaporated to give di-isopropyl 5-(2-morpholinoethyl)thien-2ylboronate which was used without further purification.Example 9Using an analogous procedure to that desc ribed in Example 5 except that the reaction mixture was heated to reflux for 2 hours, 6-bromo-4-(3-chloro-4fluoroanilino)quinazoline hydrochloride salt was re acted with di-isopropyl 5morpholinomethylthien-3-ylboronate. The reaction mixture was cooled to ambient temperature and partitioned between methylene chloride and water. The organic phase was washed with brine, dried and evaporated. The residue was purified by column chromatography using a 25:1 mixture of methylene chloride and methanol as eluent. The resultant product was recrystallised from ethyl acetate. There was thus obtained 4-(3-chloro4-fluoroanilino)-6-(5-morpholinomethylthien-3-yl)quinazoline in 30% yield;NMR Spectrum: 2.5 (t, 4H), 3.6 (t, 4H), 3.75 (s, 2H), 7.45 (t, 1H), 7.6 (d, 1H), 7.8 (m, 2H), 7.95 (d, 1H), 8.22 (m, 2H), 8.6 (s, 1H), 8.75 (d, 1H), 9.9 (broad s, 1H);Elemental Analysis: Found C, 58.5; H, 4.8; Ν, 11.7:C23H20CIFN4OS 1H2O requires C, 58.4; H, 4.7; N, 11.8%.-42The di-isopropyl 5-morpholinomethylthien-3-ylboronate used as a starting material was obtained as follows:Sodium cyanoborohydride (2 g) was added portionwise to a stirred mixture of 4-bromo-2-thiophenecarbaldehyde (4.78 g), morpholine (2.1 g), glacial acetic acid (1.8 g) and ethanol (125 ml). The mixture was stirred at ambient temperature for 1 hour. The mixture was poured into a saturated aqueous sodium bicarbonate solution and extracted with methylene chloride. The organic phase was washed with brine and evaporated. The resultant oil was partitioned between a dilute (10%) aqueous hydrochloric acid solution and methylene chloride. The aqueous phase was basified by the addition of a saturated aqueous sodium bicarbonate solution and extracted with methylene chloride. The organic extract was dried (MgSO4) and evaporated to give 4-bromo-2-morpholinomethylthiophene (3.2 g);NMR Spectrum: 2.4 (t, 4H), 3.55 (t, 4H), 3.65 (s, 2H), 6.95 (d, 1H), 7.5 (d, 1H).A portion (1.22 g) of the material so obtained was dissolved in THF (100 ml) and the solution was cooled to -78°C. Tri-isopropyl borate (0.963 g) and n-butyllithium (1.6M in hexane, 2.91 ml) were added in turn. The mixture was stirred at -78°C for 30 minutes and then allowed to warm to ambient temperature. The mixture was evaporated to give diisopropyl 5-morpholinomethylthien-3-ylboronate which was used without further purification.Example 10A mixture of 6-(2-chloroacetyl)-4-(3-chlo:'O-4-fluoroanilino)quinazoline (0.5 g) and formamide (2 ml) was stirred and heated to 140°C lor 2 hours. The mixture was cooled to ambient temperature and water was added. The precipitate was isolated and purified by column chromatography on a Cl8 reversed-phase si lica column using decreasingly polar mixtures of water and methanol (containing 0.2% of trifluoroacetic acid) as eluent. There were thus obtained in turn :4-(3-chloro-4-fluoroanilino)-6-(4-imidazolyl)quinazoline (0.135 g);NMR Spectrum: 7.54 (t, 1H), 7.78 (m, 1H), 7.94 (d, 1H), 8.07 (d, 1H), 8.12 (m, 1H), 8.38 (m, 1H), 8.81 (s, 1H), 8.82 (s, 1H), 9.01 (s, 1H);Elemental Analysis: Found C, 42.9; H, 2.5; N, 11.4;C17H,,C1FN51.4H2O 2CF3CO2H requires C, 42.5; H, 2.7; N, 11.8%; and 4-(3-chloro-4-fluoroanilino)-6-(4-oxazolyl)quinazol ine (0.056 g);NMR Spectrum: 7.53 (t, 1H), 7.8 (m, 1H), 7.93 (d, 1H), 8.12 (m, 1H), 8.42 (m, 1H), 8.65-43 (s, 1H), 8.8 (s, IH), 8.88 (s, IH), 9.1 (d, IH);Elemental Analysis: Found C, 47.0; H, 2.3; N, 11.2;C,7HhC1FN4O 1.5CF3CO2H requires C, 46.9; H, 2.3; N, 10.9%.The 6-(2-chloroacetyl)-4-(3-chloro-4-fluoroanilino)quinazoline used as a starting material was obtained as follows:Triphenylphosphine (0.063 g) was added to a stirred mixture of 6-bromo-4-(3chloro-4-fluoroanilino)quinazoline hydrochloride salt (2.34 g), triethylamine (3.4 ml), (trimethylsilyl)acetylene (1.33 ml) palladium(II) chloride (0.021 g), cuprous iodide (0.045 g) and DMF (15 ml). The mixture was stirred and heated to 90°C for 2 hours. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro4-fluoroanilino)-6-(2-trimethylsilylethynyl)quinazcline (2.2 g).A mixture of a portion (2 g) of the material so obtained, potassium carbonate (0.25 g) and methanol (100 ml) was stirred at ambient temperature for 2 hours. The mixture was acidified to pH5 by the addition of glacial aceti c acid. The resultant mixture was evaporated and the residue was partitioned between methylene chloride and water. The organic phase was dried (MgSO4) and evaporated. There was thus obtained 4-(3-chloro-4fluoroanilino)-6-ethynylquinazoline (1.68 g), m.p. 224-226°C;NMR Spectrum: 4.42 (s, IH), 7.45 (t, IH), 7.59 (d, IH), 7.8-7.93 (m, 2H), 8.23 (m, IH), 8.65 (s, IH), 8.77 (s, IH), 9.8 (broad s, IH).A mixture of a portion (1.2 g) of the material so obtained, mercuric trifluoroacetate (0.1 g), water (1 ml) and trifluoroacetic acid (15 ml) was stirred and heated to reflux for 4 hours. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. The material so obtained was triturated under methylene chloride There was thus obtained 6-acetyl-4-(3chloro-4-fluoroanilino)quinazoline (0.37 g), m.p. 213-213°C;NMR Spectrum: 2.75 (s, 3H), 7.47 (t, IH), 7.83 (m, IH), 7.88 (d, IH), 8.14 (m, IH), 8.33 (m, IH), 8.69 (s, IH), 9.19 (d, IH).Chlorine gas was led into a stirred mixture of 6-acetyl-4-(3-chloro-4-fluoroanilino)quinazoline (0.11 g), methylene chloride (40 ml) and ethanol (60 ml) and the mixture was cooled to a temperature in the range 20 to 25°C. After 10 minutes the supply of chlorine was stopped and the reaction mixture was stirred at ambient temperature for 1 hour. The mixture-44was evaporated to give 6-(2-chloroacetyl)-4-(3-chloro-4-fluoroanilino)quinazoline (0.114 g) which was used without further purification.Example 11A mixture of 6-bromo-4-(3-chloro-4-fluo]Oanilino)quinazoline (0.5 g), 2-pyridyl-trin-butyltin (J. Het. Chem.. 1990, 2165; 0.8 g), tetrakis(triphenylphosphine)palladium(0) (0.05 g) and THF (20 ml) was stirred and heated to 60°C for 4 days. The mixture was evaporated and the residue was purified by column chromatography using initially methylene chloride and then increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(2-pyridyl)quinazoline (0.11 g);NMR Spectrum: 7.45 (m, 1H), 7.47 (t, 1H), 7.88 (m, 1H), 7.9 (d, 1H), 8.03 (m, 1H), 8.18 (d, 1H), 8.22 (d, 1H), 8.63 (m, 1H), 8.66 (s, 1H), 8.75 (m, 1H), 9.19 (d, 1H);Elemental Analysis: Found C, 61.5; H, 3.6; N, 14.9;C19H12C1FN41.1H2O requires C, 61.6; H, 3.8; Ν, 15.1%.Example 12Diethyl-3-pyridylborane (0.176 g) was added to a mixture of 6-bromo-4-(3-chloro-4 fluoroanilino)quinazoline (0.53 g), powdered potassium hydroxide (0.202 g), tetra-nbutylammonium bromide (0.042 g), tetrakis(triphenylphosphine)palladium(0) (0.069 g) and THF (10 ml). The resultant mixture was stirred and heated to reflux for 16 hours. The mixture was evaporated and the residue was purified by column chromatography using initially methylene chloride and then increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-::hloro-4-fluoroanilino)-6-(3pyridyl)quinazoline (0.125 g);NMR Spectrum: 7.5 (t, 1H), 7.6 (m, 1H), 7.88 (m, 1H), 7.93 (d, 1H), 8.2 (m, 1H), 8.28 (m, 1H), 8.3 (m, 1H), 8.68 (m, 2H), 8.91 (d, 1H), 9.16 (d, 1H), 10.02 (broad s, 1H);Elemental Analysis: Found C, 64.3; H, 3.3; N, 15.6;C19H12C1FN40.25H2O requires C, 64.2; H, 3.5; N, 15.8%.-45Example 13A mixture of 6-amino-4-(3-chloro-4-fluoioanilino)quinazoline (0.576 g), 4-chloroquinazoline hydrochloride salt (0.83 g) and isopropanol (10 ml) was stirred and heated to reflux for 5 hours. The hot reaction mixt .ire was filtered and the filtrate was allowed to cool to ambient temperature. The resultant solid was isolated, washed with isopropanol and with diethyl ether and dried. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(4quinazoline dihydrochloride salt (0.86 g);NMR Spectrum: 7.54 (t, 1H), 7.8 (m, 1H), 7.92 (t, 1H), 8.0-8.2 (m, 4H), 8.38 (m, 1H), 8.97 (s, 1H), 8.98 (s, 1H), 9.06 (d, 1H), 9.28 (d, 1H), 11.75 (broad s, 1H), 12.26 (broad s, 1H);Elemental Analysis: Found C, 53.4; H, 3.4; N, 16.9;C22HI4C1FN62HC1 0.33H2O requires C, 53.2; H, 3.4; N, 16.9%.The 6-amino-4-(3-chloro-4-fluoroanilinojquinazoline used as a starting material was obtained as follows:3-Chloro-4-fluoroaniline (3.6 g) was added to a stirred mixture of 4-chloro-615 nitroquinazoline (European Patent Application No. 0566226, Example 8 thereof; 5 g); THF (10 ml) and DMF (10 ml). The resultant mixture was stirred at ambient temperature for 5 hours. The precipitate was isolated and partitioned between water and a 9:1 mixture of methylene chloride and methanol. The aqueous ph ase was neutralised by the addition of a saturated aqueous sodium bicarbonate solution and re-extracted with methylene chloride. The organic phases were combined and evaporated. The residue was triturated under a 9:1 mixture of ethanol and water. The resultant solid was isolated and dried. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-nitroquinazoline (2.5 g).A mixture of a portion (2.3 g) of the material so obtained, 10% palladium-on-carbon catalyst (0.4 g), ethanol (25 ml) and DMF (25 ml) was stirred under an atmosphere of hydrogen for 2 hours. The mixture was filtered and the filtrate was evaporated. The residue was triturated under a 4:1 mixture of ethanol and v / ater. The resultant solid was isolated and dried. There was thus obtained 6-amino-4-(3-chloro-4-fluoroanilino)quinazoline (0.35 g, 17%);NMR Spectrum: 5.6 (broad s, 2H), 7.27 (m, 1H), 7.32 (s, 1H), 7.41 (t, 1H), 7.55 (d, 1H), 7.8 (m, 1H), 8.19 (m, 1H), 8.38 (s, 1H), 9.53 (broad s, 1H);Elemental Analysis: Found C, 58.1; H, 3.6; N, 19.0;C,4H1OC1FN4requires C, 58.2; H, 3.5; N, 19.4%.-46Example 14A mixture of 6-amino-4-(3-methylanilino)quinazoline (European Patent Application No. 0566226, Example 8 thereof; 0.2 g), 2-fluoroimidazole 4-toluenesulphonic acid salt (0.2 g), 4-toluenesulphonic acid (0.26 g) and DMF (1 ml) was stirred and heated to 100°C for 16 hours. The mixture was cooled to ambient temperature and partitioned between methylene chloride and a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO4) and evaporated and the residue was purified by column chromatography using a 9:1 mixture of methylene chloride and methanol as eluent. There was thus obtained 6-(2imidazolylamino)-4-(3-methylanilino)quinazoline (0.09 g), m.p. 256-258°C;NMR Spectrum: 2.33 (s, 3H), 6.77 (d, 2H), 6.95 (d, IH), 7.24 (t, IH), 7.6 (m, 3H), 7.85 (m, IH), 8.11 (m, IH), 8.39 (s, IH), 8.94 (s, IH), 9.4 (s, IH), 11.0 (s, IH);Elemental Analysis: Found C, 68.1; H, 5.3; N, 26.4;C18H16N6requires C, 68.3; H, 5.1; N, 26.6%.The 2-fluoroimidazole 4-toluenesulphonic acid salt used as a starting material was obtained from 2-aminoimidazole using analogous procedures to those described in J. Het. Chem.. 1978, 1227 and J, Amer. Chem. Soc.. 1973,4619.Example 15 l-Methylimidazole-4-sulphonyl chloride (0.181 g) was added to a stirred mixture of6-amino-4-(3-methylanilino)quinazoline (0.25 g) and pyridine (10 ml) and the mixture was stirred at ambient temperature for 16 hours. The mixture was evaporated and the residual oily solid was washed with methylene chloride and with a saturated aqueous sodium bicarbonate solution. The solid was then washed with water and with acetone and dried. There was thus obtained 4-(3-methylanilino)-6-(l-methylimidazole-4-sulphonamido)quinazoline (0.07 g),m.p. >250°C;NMR Spectrum: (CD3SOCD3+ CD3CO2D) 2.37 (s, 3H), 3.64 (s, 3H), 6.98 (d, IH), 7.27 (t, IH), 7.5-7.8 (m, 6H), 8.2 (d, IH), 8.48 (s, IH);Elemental Analysis: Found C, 54.7; H, 4.4; N, 19.7;C19H18N6O2S 1.2H2O requires C, 54.8; H, 4.9; N, 20.2%.-47Example 16Sodium cyanoborohydride (0.126 g) was added portionwise to a stirred mixture of 6-amino-4-(3-methylanilino)quinazoline (0.25 g), 3-thiophenecarbaldehyde (0.26 ml), glacial acetic acid (0.114 ml) and ethanol (20 ml). The re sultant mixture was stirred at ambient temperature for 16 hours. The mixture was basified by the addition of a saturated aqueous sodium bicarbonate solution and evaporated. The residue was washed with water and dried. There was thus obtained 4-(3-methylanilino)-6-(3-thienylmethylamino)quinazoline (0.335 g), m.p. 207-208°C;NMR Spectrum: 2.3 (s, 3H), 4.45 (d, 2H), 6.52 (d, 1H), 6.9 (t, 1H), 7.2 (m, 1H), 7.3 (m, 3H),7.5 (m, 3H), 7.65 (m, 2H), 8.3 (s, 1H), 9.2 (broad 1H);Elemental Analysis: Found C, 68.6; H, 5.2; N, 15.3;C20H18N4S 0.3H2O requires C, 68.3; H, 5.3; N, 15.9%.Example 17Sodium cyanoborohydride (0.126 g) was added portionwise to a stirred mixture of 6-amino-4-(3-methylanilino)quinazoline (0.25 g), 2-imidazolecarbaldehyde (0.192 g), glacial acetic acid (0.114 ml) and ethanol (20 ml). The resultant mixture was stirred at ambient temperature for 3 hours. The mixture was basified by the addition of a saturated aqueous sodium bicarbonate solution and evaporated. The residue was washed with water and dried. There was thus obtained 6-(2-imidazolylmethylamino)-4-(3-methylanilino)quinazoline (0.096 g), m.p. 235-237°C;NMR Spectrum: (CD3SOCD3+ CD3CO2D, 100°C) 2.3 (s, 3H), 4.45 (d, 2H), 6.5 (t, 1H),6.9 (d, 1H), 7.1 (s, 2H), 7.3 (m, 3H), 7.5 (d, 1H), 7.65 (m, 2H), 8.3 (s, 1H), 9.2 (s, 1H),12.0 (s, 1H);Elemental Analysis: Found C, 67.4; H, 5.3; N, 24.8;C19H18N60.5H2O requires C, 67.3; H, 5.6; N, 24.8%.Example 182-Thiophenecarbonyl chloride (0.6 g) w.as added portionwise to a stirred solution of 6-amino-4-(3-chloro-4-fluoroanilino)quinazoline (1.04 g) in DMA (10 ml). The mixture was stirred at ambient temperature for 30 minutes. Methylene chloride (25 ml) was added and the-48precipitate was isolated and dried. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6(thiophene-2-carboxamido)quinazoline hydrochloride salt (1.35 g), m.p. >250°C;NMR Spectrum: 7.27 (m, IH), 7.54 (t, IH), 7.7 (m, IH), 7.9 (m, IH), 8.0 (m, 2H), 8.28 (m, 2H), 8.9 (s, IH), 9.2 (d, IH), 10.99 (s, IH), 11.5 (broad s, IH);Elemental Analysis: Found C, 52.1; H, 3.3; N, 12.9;C19H12C1FN4OS 1HC1 0.15DMA requires C, 52.5; H, 3.2; N, 13.0%.Example 19Lithium aluminium hydride (IM in diethyl ether, 7.1 ml) was added dropwise to a stirred mixture of 4-(3-chloro-4-fluoroanilino)-6-(thiophene-2-carboxamido)quinazoline hydrochloride salt (1 g) and THF (200 ml). The mixture was stirred at ambient temperature for 2 hours and then heated to 45°C for 1 hour. The mixture was cooled to ambient temperature and glacial acetic acid (5 ml) was added to destroy the excess of reducing agent. The mixture was evaporated and the residue was partitioned between methylene chloride and a 5M aqueous sodium hydroxide solution. The organic phase was washed with brine, dried and evaporated. The residue was purified by column chromatography using a 99:1 mixture of methylene chloride and methanol as eluent. The product so obtained as triturated under diethyl ether. There was thus obtained 4-(3-chloro -4-fluoroanilino)-6-(2thienylmethylamino)quinazoline (0.095 g), m.p. 193-195°C;NMR Spectrum: 4.65 (d, 2H), 6.75 (t, IH), 7.0 (m, IH), 7.4 (m, 4H), 7.55 (d, IH), 7.8 (m, IH), 8.15 (m, IH), 8.4 (s, IH), 9.4 (broad s, 1H);Elemental Analysis: Found C, 59.3; H, 3.8; N, 14.0;C19H14C1FN4S 0.1Et2O requires C, 59.4; H, 3.85; 14, 14.3%.Example 202-Furoyl chloride (0.287 g) was added pcrtionwise to a stirred solution of 6-amino4-(3-chloro-4-fluoroanilino)quinazoline (0.577 g) in DMA (3 ml) and the resultant mixture was stirred at ambient temperature for 18 hours. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro-4-fluoroanilino)6-(furan-2-carboxamido)quinazoline (0.436 g);NMR Spectrum: 6.75 (m, IH), 7.56 (m, 2H), 7.69 (m, IH), 8.0 (m, 3H), 8.27 (m, IH), 8.91-49(s, IH), 9.13 (d, IH), 10.85 (broad s, IH), 11.5 (broad s, IH); Elemental Analysis: Found C, 54.3; H, 3.1; N, 13.3; C19H12C1FN4O2requires C, 54.3; H, 3.1; N, 13.4%.Example 21Using an analogous procedure to that described in Example 19, 4-(3-chloro-4fluoroanilino)-6-(furan-2-carboxamido)quinazoline was reduced to give 4-(3-chloro-4fluoroanilino)-6-(2-furfurylamino)quinazoline in 16% yield, m.p. 197-199°C;NMR Spectrum: 4.45 (d, 2H); 6.4 (m, IH), 6.7 (m, IH), 7.3-7.6 (m, 5H), 7.8 (m, IH), 8.15 (m, IH), 8.4 (s, IH), 9.5 (m, IH);Elemental Analysis: Found C, 59.8; H, 3.7; N, 14.5;C19H14C1FN4O O.2CH2C12requires C, 59.8; H, 3.8; N, 14.5%.Example 22Using an analogous procedure to that described in Example 18, 6-amino-4-(3chloro-4-fluoroanilino)quinazoline was reacted wilh 5-isoxazolecarbonyl chloride to give 4(3-chloro-4-fluoroanilino)-6-(isoxazole-5-carboxarnido)quinazoline hydrochloride salt in 87% yield, m.p. >250°C;NMR Spectrum: 7.4 (d, IH), 7.5 (t, IH), 7.65 (m, 2H), 8.0 (m, 2H), 8.85 (d, IH), 8.9 (s, IH),11.4 (s, IH);Elemental Analysis: Found C, 50.8; H, 3.3; N, 16.3;CjgHnCIFNsOz 1HC1 0.4H2O 0.24DMA requires C, 50.8; H, 3.4; N, 16.4%.Example 23Ν,Ν’-Dicyclohexylcarbodiimide (0.416 g) was added portionwise to a stirred mixture of l,2,3-triazole-4-carboxylic acid (0.226 g) and DMA (10 ml). The resultant mixture was stirred at ambient temperature for 2 hours. A solution of 6-amino-4-(3-chloro-4fluoroanilino)quinazoline (0.576 g) in DMA (5 ml) was added and the mixture was stirred at ambient temperature for 16 hours. The mixture.was evaporated and the residue was purified by column chromatography using a 9:1:0.2 mixtur e of methylene chloride: methanol:-50triethylamine as eluent. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(l,2,3triazole-4-carboxamido)quinazoline (0.145 g);NMR Spectrum: 7.43 (m, 1H), 7.82 (d, 1H), 7.95 (m, 1H), 8.18 (m, 2H), 8.43 (s, 1H), 8.58 (s, 1H), 8.88 (d, 1H), 9.89 (s, 1H), 10.55 (s, 1H);Elemental Analysis: Found C, 55.6; H, 5.8; N, 21.4;C17H„C1FN7O 0.8H2O l.lEt3N requires C, 55.6; H, 5.7; N, 22.3%.Example 243-Pyridinecarbonyl chloride hydrochloride salt (0.107 g) was added portionwise to a stirred mixture of 6-amino-4-(3-chloro-4-fluoroanilino)-7-methylaminoquinazoline (European Patent Application No. 0635507, within Example 3 thereof; 0.11 g), triethylamine (0.101 g) and DMA (1 ml). The mixture was heated to 100°C for 3 hours. The mixture was evaporated and the residue was purified by column chromatography using a Cl8 reversed-phase silica column and decreasingly polar mixtures of water and methanol (containing 0.2% trifluoroacetic acid) as eluent. The material so obtained was suspended in water and basified by the addition of an aqueous ammonium hydroxide solution. The resultant mixture was stirred at ambient temperature for 2 hours. The solid was isolated, washed with water and dried. There was thus obtained 4-(3-chloro-4-fluoroanilino)-7-methylamino-6-(pyridine-3carboxamido)quinazoline (0.061 g), m.p. >260°C;NMR Spectrum: 2.83 (d, 3H), 6.41 (m, 1H), 6.7 (s, 1H), 7.38 (m, 1H), 7.6 (m, 1H), 7.84 (m, 1H), 8.19 (m, 1H), 8.29 (s, 1H), 8.42 (m, 1H), 8.48 (s, 1H), 8.79 (m, 1H), 9.24 (d, 1H),9.5 (s, 1H);Elemental Analysis: Found C, 55.1; H, 4.0; N, 18.4;C21H16C1FN6O 2H2O requires C, 54.9; H, 4.4; N, 18.3%.Example 25A mixture of 4-(3-chloro-4-fluoroanilinc)-6-hydroxyquinazoline (0.87 g),4-fluorobenzonitrile (0.423 g), potassium carbonate (0.828 g) and DMA (5 ml) was stirred and heated to 120°C for 4 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate and water. The organic phase was dried (MgSO4) and evaporated. The residue was triturated under a mixture of methylene chloride and methanol. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(4-cyanophenoxy)quinazoline-51 (0.54 g);NMR Spectrum: 7.21 (d, 2H), 7.43 (t, 1H), 7.72 (m, 1H), 7.82 (m, 1H), 7.88 (d, 2H), 7.93 (d, 1H), 8.18 (m, 1H), 8.39 (d, 1H), 8.68 (s, 1H);Elemental Analysis: Found C, 63.9; H, 3.0; N, 14.1;C21H12C1FN4O 0.2H2O requires C, 64.0; H, 3.2; N, 14.2%.The 4-(3-chloro-4-fluoroanilino)-6-hydroxyquinazoline used as a starting material was obtained as follows:A mixture of 6-acetoxy-4-chloroquinazo ine (European Patent Application No. 0566226, Example 34, Note c; 54 g), 3-chloro-4-fluoroaniline (35.6 g) and isopropanol (850 ml) was stirred and heated to reflux for 90 minutes and then stored at ambient temperature for 16 hours. The precipitate was isolated and washed in turn with isopropanol and diethyl ether. There was thus obtained 6-acetoxy-4-(3-chloro-4-fluoroanilino)quinazoline (43.7 g, 49%).A concentrated aqueous ammonium hydroxide solution (30% weight / volume, 35 ml) was added to a stirred mixture of 6-acetoxy-4-(3-chloro-4-fluoroanilino)quinazoline (22 g) and methanol (200 ml) and the mixture was heated to reflux for 3 hours. The mixture was evaporated and water (300 ml) was added to the residue. The solid was isolated, washed in turn with water (100 ml) and ethanol (60 ml) and dried. There was thus obtained 4-(3-chloro4-fluoroanilino)-6-hydroxyquinazoline (16.1 g, 93%);NMR Spectrum: 7.43 (t, 1H), 7.45 (m, 1H), 7.70 (:1, 1H), 7.78 (d, 1H), 7.88 (m, 1H), 8.24 (m, 1H), 8.5 (s, 1H), 9.6 (broad s, 1H), 10.1 (broad s, 1H).Example 26A mixture of 4-(3-chloro-4-fluoroanilino)-6-hydroxyquinazoline (5 g), 4-fluoronitrobenzene (2.67 g), potassium carbonate (4.74 g) and DMA (50 ml) was stirred and heated to 70°C for 10 minutes. The mixture was c ooled to ambient temperature and then added dropwise to a stirred slurry of ice and water. The resultant precipitate was isolated, washed in turn with water, with a small volume of methanol and with diethyl ether and dried. There was thus obtained 4-(3-chloro-4-fluoroanilimo)-6-(4-nitrophenoxy)quinazoline (6.8 g); NMR Spectrum: 7.27 (d, 2H), 7.43 (t, 1H), 7.75 (rn, 1H), 7.8 (m, 1H), 7.97 (d, 1H), 8.18 (m, 1H), 8.29 (d, 2H), 8.42 (d, 1H), 8.69 (s, 1¾Elemental Analysis: Found C, 58.1; H, 2.8; N, 13.4;C20H12ClFN4O3requires C, 58.5; H, 2.9; N, 13.6° / / -52Example 27A mixture of 4-(3-chloro-4-fluoroanilino)-6-(4-nitrophenoxy)quinazoline (6 g), 10% palladium-on-carbon catalyst (0.6 g) and DMA (250 ml) was stirred and heated to 60°C under an atmosphere of hydrogen for 2 hours. The mixture was filtered and the filtrate was evaporated. The residue was purified by column cliiromatography using initially methylene chloride and then increasingly polar mixtures of methylene chloride and methanol as eluent. The product so obtained was triturated under methanol. There was thus obtained 6-(4aminophenoxy)-4-(3-chloro-4-fluoroanilino)quinaxoline (2.3 g);NMR Spectrum: 5.0 (broad s, 2H), 6.63 (d, 2H), 6.84 (d, 2H), 7.42 (t, 1H), 7.45 (m, 1H), 7.78 (d, 1H), 7.85 (m, 1H), 8.08 (d, 1H), 8.17 (m, 1H), 8.57 (s, 1H), 9.75 (s, 1H);Elemental Analysis: Found C, 62.7; H, 3.8; N, 14.7;C20H14ClFN4O requires C, 63.1; H, 3.7; N, 14.7%.Example 28 tert-Butvl nitrite (0.243 g) was added to a stirred solution of 6-(4-aminophenoxy)-4(3-chloro-4-fluoroanilino)quinazoline (0.45 g) in DMF (25 ml) and the mixture was heated to 90°C for 3 hours. The mixture was cooled to ambient temperature and acidified by the addition of glacial acetic acid. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6phenoxyquinazoline (0.207 g);NMR Spectrum: 7.0-7.3 (m, 5H), 7.32 (d, 1H), 7.35-7.6 (m, 3H), 7.9 (m, 1H), 7.93 (d, 1H), 8.73 (s, 1H);Elemental Analysis: Found C, 62.6; H, 3.9; N, 11.5;C20H13ClFN3O 1H2O requires C, 62.6; H, 3.9; Ν, 11.5%.Example 294-(3-Chloro-4-fluoroanilino)-6-(4-cyanophenoxy)quinazoline (2.7 g) was added portionwise to a stirred mixture of lithium aluminium hydride (IM in THF, 10 ml) and diethyl ether (50 ml). The resultant mixture was stirred at ambient temperature for 1 hour. Glacial acetic acid was added dropwise to destroy the excess of reducing agent. The mixture was partitioned between ethyl acetate and a dilute aqueous ammonium hydroxide solution. The-53 organic phase was dried (MgSO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 6-(4-aminomethylphenoxy)-4-(3-chloro-4-fluoroanilino)quinazoline (1.8 g);NMR Spectrum: 3.23 (s, 2H), 3.8 (broad s, 2H), 7.18 (d, 2H), 7.43 (d, 2H), 7.47 (t, IH), 7.6 (m, IH), 7.86 (m, IH), 7.9 (d, IH), 8.22 (m, IH), 8.31 (d, IH), 8.65 (s, IH);Elemental Analysis: Found C, 61.0; H, 4.4; N, 13.3;C21H16C1FN4O 1H2O requires C, 61.1; H, 4.4; N, 13.6%.Example 30Di-(2-bromoethyl)ether (0.28 g) was added to a stirred mixture of 6-(4aminomethylphenoxy)-4-(3-chloro-4-fluoroanilino)quinazoline (0.5 g), potassium carbonate (0.33 g) and DMA (5 ml). The resultant mixture was stirred and heated to 70°C for 30 minutes. The mixture was evaporated and the residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-(4morpholinomethylphenoxy)quinazoline (0.192 g);NMR Spectrum: 2.37 (broad s, 4H), 3.49 (s, 2H), 2.62 (broad s, 4H), 7.02 (d, 2H), 7.34 (d, 2H), 7.41 (t, IH), 7.58 (m, IH), 7.82 (m, 2H), 8.2 (m, 2H), 8.62 (s, IH), 9.79 (broad s, IH);Elemental Analysis: Found C, 63.4; H, 5.0; N, 12.0;C25H22C1FN4O20.5H2O requires C, 63.4; H, 4.9; N, 11.8%.Example 31A mixture of 6-bromomethyl-4-(3-methylanilino)quinazoline (European Patent Application No. 0566226, Example 35 thereof; 0.3 g), imidazole (0.264 g) and ethanol (4 ml) was stirred at ambient temperature for 4 hours. The mixture was evaporated and the residue was purified on a Cl8 reversed-phase silica column using decreasingly polar mixtures of water and methanol, each containing 0.2% trifluoroacetic acid, as eluent. There was thus obtained 6-(l-imidazolylmethyl)-4-(3-methylanilino)quinazoline (0.27 g), m.p. 151-155°C; NMR Spectrum: 2.37 (s, 3H), 5.66 (s, 2H), 7.07 (d, IH), 7.36 (t, IH), 7.53 (s, IH), 7.58-54(d, ΙΗ), 7.74 (m, 1H), 7.8 (d, 1H), 7.88 (d, 1H), 7.97 (m, 1H), 8.69 (s, 1H), 8.79 (s, 1H), 9.26 (s, 1H), 10.78 (broad s, 1H);Elemental Analysis: Found C, 49.1; H, 3.8; N, 12.2;CI9H17N52CF3CO2H 1H2O requires C, 49.2; H, 3.7; N, 12.5%.Example 32A mixture of 4-(3-chloro-4-fluoroanilino)-6-hydroxy-7-methoxyquinazoline (0.5 g), 2-chloromethylpyridine hydrochloride salt (0.282 g), potassium carbonate (1.5 g) and DMF (15 ml) was stirred and heated to 80°C for 2 hours. The mixture was cooled to ambient temperature and poured into water. The precipitate was isolated and recrystallised from methanol. There was thus obtained 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(2pyridylmethoxy)quinazoline (0.37 g);NMR Spectrum: 3.98 (s, 3H), 5.35 (s, 2H), 7.26 (s, 1H), 7.4 (m, 2H), 7.64 (m, 1H), 7.8 (m, 1H), 7.9 (m, 1H), 8.01 (s, 1H), 8.15 (m, 1H), 8.51 (s, 1H), 8.62 (m, 1H), 9.56 (s, 1H); Elemental Analysis: Found C, 61.1; H, 4.0; N, 13.5;C21H16C1FN4O2requires C, 61.4; H, 3.9; N, 13.6%.The 4-(3-chloro-4-fluoroanilino)-6-hydroxy-7-methoxyquinazoline used as a starting material was obtained as follows:6,7-Dimethoxy-3,4-dihydroquinazolin-4-one (European Patent Application No. 0566226, Example 1 thereof; 26.5 g) was added pcrtionwise to stirred methanesulphonic acid (175 ml). L-Methionine (22 g) was added and the resultant mixture was stirred and heated to reflux for 5 hours. The mixture was cooled to ambient temperature and poured onto a mixture (750 ml) of ice and water. The mixture was neutralised by the addition of a concentrated (40%) aqueous sodium hydroxide solution. The precipitate was isolated, washed with water and dried. There was thus obtained 6-hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one (Π.5 g).After repetition of the previous reaction, ei mixture of 6-hydroxy-7-methoxy-3,4dihydroquinazolin-4-one (14.18 g), acetic anhydride (110 ml) and pyridine (14 ml) was stirred and heated to 100°C for 2 hours. The mixture was poured onto a mixture (200 ml) of ice and water. The precipitate was isolated, washed with water and dried. There was thus obtained 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one (13 g, 75%);-55NMR Spectrum: 2.3 (s, 3H), 3.8 (s, 3H), 7.3 (s, IH), 7.8 (s, IH), 8.1 (s, IH), 12.2 (broad s, IH).After repetition of the previous steps, a m ixture of 6-acetoxy-7-methoxy-3,4dihydroquinazolin-4-one (15 g), thionyl chloride (215 ml) and DMF (4.3 ml) was stirred and heated to 90°C for 4 hours. The mixture was cooled to ambient temperature and the thionyl chloride was evaporated. There was thus obtained 6-acetoxy-4-chloro-7methoxyquinazoline hydrochloride salt which was used without further purification.A mixture of the material so obtained, 3-ehloro-4-fluoroaniline (9.33 g) and isopropanol (420 ml) was stirred and heated to 90°C for 5 hours. The mixture was cooled to ambient temperature and the precipitate was isolated, washed in tum with isopropanol and methanol and then dried. There was thus obtained 6-acetoxy-4-(3-chloro-4-fluoroanilino)7-methoxyquinazoline hydrochloride salt (14 g, 56%);NMR Spectrum: 2.4 (s, 3H), 4.0 (s, 3H), 7.5 (t, IH), 7.6 (s, IH), 7.75 (m, IH), 8.05 (m, IH), 8.8 (s, IH), 8.95 (s, IH), 11.5 (broad s, IH).A concentrated aqueous ammonium hydroxide solution (30% weight / volume, 7.25 ml) was added to a stirred mixture of the material so obtained and methanol (520 ml). The mixture was stirred at ambient temperature for 17 hours and then heated to 100°C for 1.5 hours. The mixture was cooled and the precipitate was isolated and dried. There was thus obtained 4-(3-chloro-4-fluoroanilino)-6-hydroxy-7 -methoxyquinazoline (10.62 g, 95%), m.p. >270°C (decomposes);NMR Spectrum: 4.0 (s, 3H), 7.2 (s, IH), 7.4 (t, IH), 7.8 (s, IH), 7.85 (m, IH), 8.2 (m, IH),8.5 (s, IH), 9.45 (s, IH), 9.65 (s, IH).Example 33Using an analogous procedure to that described in Example 32, 4-(3-chloro-4fluoroanilino)-6-hydroxy-7-methoxyquinazoline was reacted with 3-chloromethylpyridine, hydrochloride salt to give 4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-pyridylmethoxy)quinazoline in 18% yield;NMR Spectrum: 3.93 (s, 3H), 5.28 (s, 2H), 7.16 (s, IH), 7.4 (m, 2H), 7.75 (m, IH), 7.95 (m, IH), 8.1 (m, 2H), 8.4 (s, IH), 8.6 (m, IH), 8.75 (m, IH);Elemental Analysis: Found C, 61.0; H, 3.9; N, 13.5;C21H16C1FN4O2requires C, 61.4; H, 3.9; N, 13.6%.-56Example 34A mixture of 6-bromomethyl-4-(3-methylanilino)quinazoline (0.3 g), 4-mercaptol, 2,3-triazole disodium salt (0.535 g) and DMF (3 ml) was stirred at ambient temperature for 3 hours. The mixture was evaporated and the residue was purified by column chromatography using a Cl 8 reversed-phase silica column and a 1:1 mixture of methanol and water, each containing 0.2% trifluoroacetic acid, as eluent. There was thus obtained 4-(3methylanilino)-6-(l,2,3-triazol-4-ylthiomethyl)quirLazoline (0.22 g), m.p. 64-68°C;NMR Spectrum: 2.38 (s, 3H), 4.36 (s, 2H), 7.15 (d, IH), 7.38 (t, IH), 7.49 (m, 2H), 7.83 (s, IH), 8.0 (m, IH), 8.58 (d, IH), 8.87 (s, IH), 11.2 (broad s, IH);Elemental Analysis: Found C, 47.5; H, 3.4; Ν, 16.C;C18H16N6S 1.6CF3CO2H 0.25H2O requires C, 47.6:, H, 3.4; N, 15.7%.Example 35Using an analogous procedure to that described in Example 34, 6-bromomethyl-4(3-methylanilino)quinazoline was reacted with 2-ir ercapto-l-methylimidazole sodium salt [prepared by the reaction of 2-mercapto-l-methylimidazole and sodium ethoxide in ethanol] to give 4-(3-methylanilino)-6-(N-methylimidazol-2-ylthiomethyl)quinazoline in 65% yield,m. p. 137-139°C;NMR Spectrum: 2.42 (s, 3H), 3.6 (s, 3H), 4.48 (s, 2H), 6.97 (d, IH), 7.13 (d, IH), 7.39 (t, IH), 7.55 (m, 2H), 7.6 (d, IH), 7.83 (d, IH), 7.93 (m, IH), 8.5 (s, IH), 8.83 (s, IH), 10.9 (broad s, IH);Elemental Analysis: Found C, 48.3; H, 3.6; Ν, 11.6;C20H19N5S 2CF3CO2H 0.5H2O requires C, 48.1; H, 3.5; Ν, 11.7%.Example 36A mixture of 6-bromomethyl-4-(3-methy lanilino)quinazoline (1.6 g), 2-mercaptoimidazole (0.316 g) and DMF (20 ml) was stirred and heated at 60°C for 6 hours. The mixture was cooled to ambient temperature and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 6-(2-imidazolylthiomethyl)-4-(3-methylanilino) quinazoline (0.43 g), m.p. 217-219°C;NMR Spectrum: 2.33 (s, 3H), 4.45 (s, 2H), 6.97 (d, IH), 7.12 (s, 2H), 7.29 (m, IH), 7.64-57(m, 2H), 7.72 (m, 2H), 8.47 (s, 1H), 8.57 (s, 1H);Elemental Analysis: Found C, 65.8; H, 4.6; N, 19.9;C19H17N5S requires C, 65.7; H, 4.9; N, 20.2%.Example 37Using an analogous procedure to that described in Example 34, 6-bromomethyl-4(3-methylanilino)quinazoline was reacted with 2-mercaptobenzimidazole sodium salt to give 6-(2-benzimidazolylthiomethyl)-4-(3-methylanilino)quinazoline in 59% yield, m.p. 123-129°C;NMR Spectrum: 2.34 (s, 3H), 4.77 (s, 2H), 6.96 (d;1H), 7.13 (m, 2H), 7.28 (t, 1H), 7.46 (broad s, 2H), 7.68 (m, 3H), 7.96 (m, 1H), 8.57 (s, 1H), 8.65 (d, 1H), 9.79 (broad s, 1H); Elemental Analysis: Found C, 64.9; H, 5.3; N, 15.S';C23H19N5S 1.6H2O O.ICH3OH requires C, 64.5; H. 5.3; N, 16.3%.Example 38Using an analogous procedure to that described in Example 5, 6-bromo-4-[3methyl-4-(2-pyridylmethoxy)anilino]quinazoline dihydrochloride salt was reacted with diisopropyl 2-thienylboronate to give 4-[3-methyl-4-(2-pyridylmethoxy)anilino]-6-(2-thienyl)quinazoline in 70% yield, m.p. 205-206°C;NMR Spectrum: 2.3 (s, 3H), 5.2 (s, 2H), 7.0 (d, 1H), 7.2 (m, 1H), 7.35 (m, 1H), 7.5 (m, 3H),7.6 (m, 1H), 7.7 (m, 1H), 7.75 (d, 1H), 7.85 (m, IN), 8.1 (m, 1H), 8.48 (s, 1H), 8.55 (m, 1H), 8.75 (d, 1H), 9.8 (broad s, 1H);Elemental Analysis: Found C, 70.8; H, 4.7; N, 13.0;C25H20N4OS requires C, 70.7; H, 4.75, N, 13.2%.The 6-bromo-4-[3-methyl-4-(2-pyridylmethoxy)anilino]quinazoline dihydrochloride salt used as a starting material was obtained as follows:Sodium hydride (60% dispersion in mineral oil, 1.24 g) was added to a solution of 2-pyridylmethanol (2.49 ml) in NMP (100 ml) and the mixture was stirred at ambient temperature for 15 minutes. 2-Fluoro-5-nitrotoluene (4 g) was added and the mixture was heated to 140°C for 2.5 hours. The mixture was cooled to ambient temperature, poured into water (300 ml) and stirred for 30 minutes. The precipitate was isolated, washed with water and dried. The material so obtained was purified by column chromatography using-58increasingly polar mixtures of methylene chloride and methanol as eluent. There was thus obtained 5-nitro-2-tolyl 2-pyridylmethyl ether (1.61 g, 26%);NMR Spectrum: 2.32 (s, 3H), 5.35 (s, 2H), 7.21 (d, 1H), 7.35 (m, 1H), 7.55 (d, 1H), 7.85 (m, 1H), 8.09 (m, 1H), 8.1 (s, 1H), 8.6 (m, 1H).A mixture of 5-nitro-2-tolyl 2-pyridylmethyl ether (2 g), iron powder (1 g), concentrated hydrochloric acid (1 ml), water (2 ml) and ethanol (50 ml) was stirred and heated to reflux for 4 hours. The mixture was allowed to cool to ambient temperature, basified by the addition of 2M aqueous sodium hydroxide solution and extracted with methylene chloride. The organic phase was dried (MgSO4) and evaporated. There was thus obtained 5-amino-2tolyl 2-pyridylmethyl ether in 97% yield;NMR Spectrum: 2.09 (s, 3H), 4.61 (s, 2H), 5.0 (s, 2H), 6.32 (m, 1H), 6.42 (d, 1H), 6.67 (d, 1H), 7.31 (m, 1H), 7.50 (d, 1H), 7.81 (m, 1H), 8.54 (m, 1H).Using an analogous procedure to that des cribed in the third paragraph of the portion of Example 1 which is concerned with the preparation of starting materials, except that the product was recrystallised from a mixture of methanol and ethanol, 6-bromo-4chloroquinazoline was reacted with 5-amino-2-tolyl 2-pyridylmethyl ether to give 6-bromo-4[3-methyl-4-(2-pyridylmethoxy)anilino)quinazoline dihydrochloride salt in 68% yield, m.p. 232-234°C;NMR Spectrum: 2.3 (s, 3H), 5.35 (s, 2H), 7.13 (m, 1H), 7.52 (m, 3H), 7.63 (d, 1H), 7.9 (d, 1H), 8.08 (m, 1H), 8.25 (m, 1H), 8.7 (m, 1H), 8.92 (s, 1H), 9.17 (d, 1H), 11.62 (d, 1H); Elemental Analysis: Found C, 48.4; H, 4.2; N, 10.6;C21H17BrN4O 2HC1 1.5H2O requires C, 48.4; H, 4.25; N, 10.7%.Example 39Using an analogous procedure to that described in Example 5, 6-bromo-4-[3methyl-4-(2-pyridylmethoxy)anilino]quinazoline dihydrochloride salt was reacted with diisopropyl 3-furylboronate to give 6-(3-furyl)-4-[3-methyl-4-(2-pyridylmethoxy)anilino]quinazoline in 55% yield, m.p. 206-208°C;NMR Spectrum: 2.32 (s, 3H), 5.22 (s, 2H), 7.05 (d, 1H), 7.15 (d, 1H), 7.36 (m, 1H), 7.55 (m, 3H), 7.75 (d, 1H), 7.87 (m, 2H), 8.1 (m, 2H), 8.33 (d, 1H), 8.48 (s, 1H), 8.6 (m, 1H), 8.69 (d, 1H), 9.62 (s, 1H);Elemental Analysis: Found C, 73.2; H, 4.9; N, 13.6;-59C25H20N4O2requires C, 73.5; H, 4.9; N, 13.7%.The di-isopropyl 3-furylboronate used as a starting material was obtained as follows:n-Butyllithium (1.6M in hexane, 1 ml) w,;ts added dropwise to a stirred mixture of 5 3-bromofuran (0.21 g), tri-isopropyl borate (0.4 ml) and THF (5 ml) which had been cooled to-78°C. The mixture was stirred and allowed to warm to ambient temperature. The mixture was evaporated to give the required starting material which was used without further purification.Example 40The following illustrate representative pharmaceutical dosage forms containing the compound of formula I, or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:(a) Tablet I mg / tabletCompound X............................................. 100Lactose Ph.Eur.......................................... 182.75Croscarmellose sodium.............................. 12.0Maize starch paste (5% w / v paste)............ 2.25Magnesium stearate................................... 3.0 (b) Tablet II mg / tabletCompound X............................................. 50Lactose Ph.Eur........................................... 223.75Croscarmellose sodium.............................. 6.0Maize starch............................................... 15.0Polyvinylpyrrolidone................................. 2.25Magnesium stearate................................... 3.0-60(c) Tablet III mg / tabletCompound X............................................. 1.0Lactose Ph.Eur........................................... 93.25Croscarmellose sodium.............................. 4.0Maize starch paste (5% w / v paste)............ 0.75Magnesium stearate 1.0 (d) Capsule mg / capsuleCompound X.............................................. 10Lactose Ph. Eur.......................................... 488.5Magnesium stearate................................... 1.5 (e) Injection I (50 mg / ml)Compound X............................................. 5.0% w / v1M Sodium hydroxide solution................. 15.0% w / v0.1M Hydrochloric acid (to adjust pH to 7.6)Polyethylene glycol 400............................ 4.5% w / vWater for injection to 100% (f) Injection II (10 mg / ml)Compound X............................................. 1.0% w / vSodium phosphate BP................................ 3.6% w / v0.1M Sodium hydroxide solution.............. 15.0% v / vWater for injection to 100% (g) Injection III (lmg / ml.buffered to pH6)Compound X............................................. 0.1% w / vSodium phosphate BP................................ 2.26% w / vCitric acid................................................... 0.38% w / vPolyethylene glycol 400............................. 3.5% w / vWater for injection to 100%-61 NoteThe above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Claims

CLAIMS 1. A quinazoline derivative of the formula I Q2 X wherein X1 is a direct link; wherein Q1 is a 5-membered heteroaryl moiety containing one heteroatom selected from oxygen and sulphur, which heterocyclic moiety is a single ring or is fused to a benzo ring, and 10 Q1 optionally bears up to 3 substituents selected from halogeno, hydroxy, amino, trifluoromethoxy, trifluoromethyl, cyano, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (2-4C)alkenyloxy, (2-^'-C)alkynyloxy, (l-3C)alkylenedioxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-l-yl, 4-(l-4C)alkylpiperazin-l-yl, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl, 15 N,N-di-[(l-4C)alkyl]carbamoyl, amino-(l-4C)alkyl, (l-4C)alkylamino-(l-4C)alkyl, di-[(l-4C)alkyl]amino-(l-4C)alkyl, pyrrolidin-1 -y -(1-4C)alkyl, piperidino-(l-4C)alkyl, morpholino-(l -4C)aikyl, piperazin-l-yl-(l-4C)aIkyl, 4-(l-4C)alkylpiperazin-l-yl-(l-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (1 -4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (l-4C)alkylamino-(2-4C)alkoxy, di-[(l-4C)alkyl]amino-(2-4C)alkoxy, 20 pyrrolidin-l-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-l-yl-(2-4C)alkoxy, 4-(l-4C)alkylpiperazin-l-yl-(2-4C)alkoxy, (1 -4C)alkylthio-(2-4C)alkoxy, (1 -4C)alkylsulphinyl-(2-4C)alkoxy, (l-4C)alkylsulphonyl-(2-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (l-4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, 25 (1 -4C)alkylamino-(2-4C)alkylamino, di-[( 1 -4C)alkyl]amino-(2-4C)alkylamino, pyrrolidin-l-yl-(2-4C)alkylamino, piperidino-(2-4C)alkylamino, morpholino-(2-4C)alkylamino, piperazin-1 -yl-(2-4C)alkylamino, 4-(l-4C)alkylpiperazin-l-yl-(2-4C)alkylamino, N-(I-4C)alkyl-halogeno-(2-4C)alkylamino, N-(l-4C)alkyl-hydroxy-(2-4C)alkyl amino, N-(l-4C)alkyl-(l-4C)alkoxy-(2-4C)alkylamino, 30 halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino, (l-4C)alkoxy-(2-4C)alkanoylamino, (3-4C)alkenoylamino, (3-4C)alkynoylamino, amino-(2-4C)alkanoylamino, (l-4C)alkylamino-(2-4C)alkanoylamino, di-[(l-4C)alkyl]amino-(2-4C)alkanoylamino, pyrro?idin-l-yl-(2-4C)alkanoylamino, -63 · piperidino-(2-4C)alkanoylamino, morpholino-(2-4C)alkanoylamino, piperazin-l-yl-(2-4C)alkanoylamino and 4-(l-4Cjalkylpiperazin-l-yl-(2-4C)alkanoylamino, and wherein any of the above-mentioned substituents comprising a CH2 (methylene) group which is not attached to a halogeno, SO or SO2 group or to a Ν, O or S atom optionally bears on said CH2 group a substituent selected from hyc / roxy, amino, (l-4C)alkoxy, (l-4C)alkylamino and di-[(l-4C)alkyl]amino; ................ wherein m is 1 or 2 and each R1 is independently hydrogen, halogeno, trifluoromethyl, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (l-4C)alkoxycarbamoyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl] amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl or N,N-di-[(l-4C)alkyl]carbamoyl; and wherein Q is phenyl optionally bearing up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-(l-4C)alkylcarbamoyl, or Q is a group of the formula II wherein X2 is a group of the formula CO, C(R3)2, CH(OR3), C(R3)2-C(R3)2, C(R3)=C(R3), C=C, CH(CN), O, S, SO, SO2, N(R3), CON(R3), SO2N(R3), N(R3)CO, N(R3)SO2, OC(R3)2, SC(R3)2, C(R3)2O or C(R3)2S wherein each R3 is independently hydrogen or (l-4C)a!kyl, Q3 is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing up to 3 heteroatoms selected from oxygen, nitrogen and sulphur, which heteroaryl moiety is a single ring or is fused to a benzo ring, and wherein said phenyl or naphthyl group or heteroaryl moiety optionally bears up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-[(l-4C)alkyl]carbamoyl, n is 1, 2 or 3 and each R4 is independently hydrogen, halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino or (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof.

2. A quinazoline derivative of the formula I as claimed in claim 1 wherein X1 is a direct link; wherein Q1 is a 5-membered heteroaryl moiety containing one heteroatom selected from oxygen and sulphur, which heterocyclic moiety is a single ring or is fused to a benzo ring, and -64 · Q1 optionally bears up to 3 substituents selected from halogeno, hydroxy, amino, trifluoromethoxy, trifluoromethyl, cyano, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)a!koxy, (2-4C)alkenyloxy, (2-4C)alkynyloxy, (l-3C)alkylenedioxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, pyrrolidin-l-yl, piperidino, morpholino, piperazin-1-yl, 4-(l-4C)alkylpiperazin-l-yl, (2-4C')alkanoylamino, N-(l-4C)alkylcarbamoyl, N,N-di-[(l-4C)alkyl]carbamoyl, amino-(l-4C)alkyl, (l-4C)alkylamino-(l-4C)alkyl, di-[(l-4C)alkyl]amino-(l-4C)alkyl, pyrrolidin-1-y 1-(l-4C)alkyl, piperidino-(l-4C)alkyl, morpholino-( 1 -4C)alkyl, piperazin-1 -yl-(1 -4C)alkvl, 4-(1 -4C)alkylpiperazin-1 -yl-(l-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (1 -4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (l-4C)alkylamino-(2-4C)alkoxy, di-[(l-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1 -yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-l-yl-(2-4C)alkoxy, 4-(l-4C)alkylpiperaz;in-l-yl-(2-4C)alkoxy, (l-4C)alkylthio-(2-4C)alkoxy, (1 -4C)alkylsulphinyl-(2-4C)alkoxy, (1 -4C)alkylsulphonyl- (2-4C)alkoxy, halogeno-(2-< ICjalkylamino, hydroxy- (2-4C)alkylamino, (l-4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (l-4C)alkylamino-(2-4C)alkylamino, di-[(l-4C)alkyl]amino-(2-4C)alkylamino, pyrrolidin-1 -yl-(2-4C)alkylamino, piperidino-(2-4C)alkylamino, morpholino-(2-4C)alkylamino, piperazin-l-yl-(2-4 C)alkylamino, 4-(l-4C)alkylpiperazin-l-yl-(2-4C)alkylamino, N-( l-4C)alkyl-halogeno(2-4C)alkylamino, N-(l -4C)alkyl-hydroxy-(2-4C)aLkylamino, N-(l-4C)alkyl-(l-4C)alkoxy-(2-4C)alkylamino, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino, (1 -4C)alkoxy-(2-4C)alkanoylamino, (3-4C)alkenoy!amino, (3-4C)alkynoylamino, amino-(2-4C)alkanoylamino, (l-4C)alkylamino-(2-4C)alkanoylamino, di-[(l-4C)alkyl]amino-(2-4C)alkanoylamino, pyrrolidin-l-yl-(2-4C)alkanoylamino, piperidino-(2-4C)alkanoylamino, morpholino-(2-4C)alkanoylamino, piperazin-1 -yl-(2-4C)alkanoylamino and 4-( 1 -4C)aikylpiperazin-1 -yl-(2-4C)alkanoylamino, and wherein any ofthe above-mentioned substituents comprising a CH2 (methylene) group which is not attached to a halogeno, SO or SO2 group or to a N, O or S atom optionally bears on said CH2 group a substituent selected from hydroxy, amino, (l-4C)alkoxy, (l-4C)alkylamino and di-[(l-4C)alkyl]amino; wherein m is 1 or 2 and each R1 is independently hydrogen, halogeno, trifluoromethyl, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (l-4C)alkoxycarbamoyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl or N,N-di-[(l-4C)alkyl]carbamoyl; and wherein Q is phenyl which optionally bears up to 3 substituents selected from halogeno, trifluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-(l-4C)alkylcart)amoyl; -65 or a pharmaceutically-acceptable salt thereof.

3. A quinazoline derivative of the formula I a s claimed in claim 1 wherein X1 is a direct link; Q1 is 2-furyl, 3-furyl, 2-thienyl or 3-thienyl which optionally bears a substituent selected from methyl, aminomethyl, 2-aminoethyl, methylaminomethyl, 2-methylaminoethyl, dimethylaminomethyl, 2-dimethylaminoethyl, pyrrolidin-l-ylmethyl, 2-pyrrolidin-l-ylethyl, piperidinomethyl, 2-piperidinoethyl, morpholinomethyl, 2-morpholinoethyl, piperazin-1-ylmethyl, 2-piperazin-l-ylethyl, 4-me1faylpiperazin-l-ylmethyl and 2-(4-m ethylpiperazin-1 -yl)ethyl; m is 1 and R1 is hydrogen or methoxy; and Q is phenyl which optionally bears 1, 2 or 3 substituents selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl and methoxy, or Q is a group of the formula II wherein X2 is a group of the formula CO or OCH2, Q3 is phenyl or 2-pyridyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo, methyl and methoxy, n is 1 and R4 is hydrogen, fluoro, chloro, bromo or methyl; or a pharmaceutically-acceptable acid-addition salt thereof.

4. A quinazoline derivative of the formula I as claimed in claim 1 wherein X1 is a direct link; Q1 is 2-furyl, 3-furyl, 2-thienyl or 3-thienyl which optionally bears a substituent selected from aminomethyl, morpholinomethyl and 2-morpholinoethyl; m is 1 and R1 is hydrogen or methoxy; and Q2 is phenyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo and methyl; or a pharmaceutically-acceptable acid-addition salt thereof.

5. The quinazoline derivative of the fonnula I as claimed in claim 1 selected from:4-(3-chloro-4-fluoroanilino)-6-(3-furyl)quinazoline, 4-(3-chloro-4-fluoroanilino)-6-(2-thienyl)quinazolir.e, 4-(3-chloro-4-fluoroanilino)-6-[5-(2-morpholmoethyl)thien-2-yl]quinazoline and 4-(3-chloro-4-fluoroanilino)-6-(5-morpholinomethy[thien-3-yl)quinazoline; or a pharmaceutically-acceptable acid-addition salt thereof.

6. A quinazoline derivative of the formula I as claimed in claim 1: wherein X1 is a direct link; Q1 is thienyl which bears a substituent selected from amino-(l-4C)alkyl, (l-4C)alkylamino(1 -4C)alkyl, di-[(1 -4C)alkyl]amino-( 1 -4C)alkyl, pyrrolidin-1 -yl-( 1 -4C)alkyl, piperidino-(l-4C)alkyl, morpholino-(l-4C)alkyl, piperazin-l-yl-(l-4C)alkyl and 4-( 1 -4C)alkylpiperazin-1 -yl-( 1 -4C)alkyl; m is 1 and R1 is hydrogen; and Q is phenyl which optionally bears up to 3 substituents selected from halogeno, tri fluoromethyl, cyano, hydroxy, amino, nitro, carboxy, carbamoyl, (l-4C)alkoxycarbonyl, (l-4C)alkyl, (l-4C)alkoxy, (l-4C)alkylamino, di-[(l-4C)alkyl]amino, (2-4C)alkanoylamino, N-(l-4C)alkylcarbamoyl and N,N-di-(l-4C)alkylcarbamoyl; or a pharmaceutically-acceptable salt thereof.

7. A quinazoline derivative of the fonnula I as claimed in claim 1 wherein X] is a direct link; Q1 is 2-thienyl which optionally bears a substituent selected from methyl, aminomethyl, 2-aminoethyl, methylaminomethyl, 2-methylaminc ethyl, dimethylaminomethyl, 2-dimethylaminoethyl, pyrrolidin-l-ylmethyl, 2-pyrrolidin-l-ylethyl, piperidinomethyl, 2-piperidinoethyl, morpholinomethyl, 2-morpholin:)ethyl, piperazin-l-ylmethyl, 2-piperazin-l-ylethyl, 4-methylpiperazin-l-ylmethyl and 2-(4-methylpiperazin-l-yl)ethyl; m is 1 and R1 is hydrogen or methoxy; and Q2 is phenyl which optionally bears 1, 2 or 3 substituents selected from fluoro, chloro, bromo, trifluoromethyl, cyano, methyl and methoxy; or a pharmaceutically-acceptable acid-addition salt thereof.

8. A quinazoline derivative of the formula I as claimed in claim 1 wherein X1 is a direct link; Q1 is 2-thienyl which optionally bears a substituent selected from aminomethyl, morpholinomethyl and 2-morpholinoethyl; m is 1 and R1 is hydrogen or methoxy; and Q is phenyl which optionally bears 1 or 2 substituents selected from fluoro, chloro, bromo and methyl; or a pharmaceutically-acceptable acid-addition salt thereof.

9. The quinazoline derivative of the formula I as claimed in claim 1 :4-(3-chloro-4-fluoroanilino)-6-[5-(2-morpholinoethyl)thien-2-yl]quinazoline; or a pharmaceutically-acceptable acid-addition salt thereof. -6Ί 10. A process for the preparation of a quinazo line derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 9 which comprises:5 (a) the reaction of a quinazoline of the formula HI III wherein Z is a displaceable group, with an aniline of the formula Q -NH2; (b) for the preparation of those compounds c f the formula I wherein X1 is a direct link, the reaction of a quinazoline of the formula IV Q2 IV 1 12 wherein Z is a displaceable group, with an organoboron reagent of the formula Q -B(L )(L ) wherein each L and L , which may be the same or different, is a suitable ligand; (c) for the preparation of those compounds ofthe formula I wherein X1 is a direct link, the reaction of a quinazoline of the formula V Q2 X 1[A V wherein each of L and L , which may be the same or different, is a suitable ligand, with a compound of the formula Q’-Z wherein Z is a displaceable group; (d) for the production of those compounds of the formula I which possess an aminomethyl substituent, the reduction of a compound of the formula I which possesses a 20 cyano substituent; or (e) for the production of those compounds of the formula I which possess an amino substituent, the reduction of a compound of the formula I which possesses a nitro substituent; -68and when a pharmaceutically-acceptable salt of a quinazoline derivative of the formula I is required it may be obtained by reaction of said compound using a conventional procedure. 5 11. A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1 to 9 in association with a pharmaceutically-acceptable diluent or carrier.

12. The use of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable10 salt thereof, as claimed in any one of claims 1 to 9 in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.